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ABSTRACT

Tissue engineering is an emerging field that came from the fields of medicine,
materials science, and engineering. The foundation of tissue engineering uses a paradigm that
incorporates cells, biomaterials, and exogenous factors to create living tissues for medical,
pharmaceutical, and research purposes. Within the last 100 years, biomaterials have been
developed to solve many medical and research problems. As biomaterials have developed
throughout the years new materials have been developed to have specific properties
appropriate for medical applications. Fumarate is a naturally derived molecule in the body
and has been found useful for developing polyesters that can be crosslinked into degradable
biomaterials. This work explores a new method for synthesizing oligo(poly(ethylene glycol)
fumarate) (OPF) and poly(butylene fumarate) (PBF). OPF was used to create a positively
charged hydrogel platform for aortic valve engineering and PBF was synthesized with
v

different types of butanediol to modify material properties for bone engineering. Conclusions
show that a new acid scavenger free synthesis method creates OPF and PBF with reduced
hydrochloric acid and fewer post-processing steps. Oligo(poly(ethylene glycol) fumarate) can
be photocrosslinked into hydrogels with positively charged functional groups for
encapsulation of valvular cells. Finally, PBF material properties can be chemically controlled
by the type of butanediol used and they can be crosslinked into hard plastic films. Overall,
the contributions of this dissertation will aid in the development of a new application for
currently used biomaterial (OPF) for soft tissue engineering as well as develop and
characterize a new variation of PBF for bone tissue engineering.
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Chapter 1
Introduction

1. Origins and Applications of Fumarate
Fumarate is a molecule that is naturally produced and used in the human body.
Synthetically derived fumarate-base molecules and polymers have been applied to
pharmaceuticals, manufacturing, and, more specifically, tissue engineering applications.
Fumarate is a type of butenedioic acid which is a four-carbon molecule containing an ⍺,βunsaturated carbonyl group. There are two isomers of butenedioic acid of which fumaric acid
is the trans-isomer and maleic acid is the cis-isomer. Fumarate is the salt and ester form of
the organic molecule fumaric acid (FA) (Figure 1-1). This molecule contains dicarboxylic
acid and ⍺,β-unsaturated double bonds and is a colorless, odorless, crystalline powder that is
found throughout nature but was first isolated and named after the Fumaria officinalis
plant.1,2 The molecular structure and material properties have made FA useful throughout the
food, pharmaceutical, and polymer industry. Federal and Drug Administration (FDA) and
World Health Organization (WHO, E297) have found FA practically non-toxic as a food
additive for human and animal consumption.3,4 It has been used as a cheap acidulant or
preservative for beverages and baked goods. It also has a similar sour taste as tartaric acid
and citric acid making it an inexpensive flavor enhancer option for foods and drinks.
Found throughout nature, FA is produced in the human body in the citric acid and
urea cycles. In the citric acid cycle, succinate is dehydrated through the succinate
dehydrogenase enzyme to form FA. In this intermediate step, a flavin adenine dinucleotide
1

(FADH) is protonated to form an FADH2, which is a molecule used in cellular respiration.
Within hepatocytes, fumarate can be transferred into the cytosol and used in the urea cycle.
During the urea cycle, succinate is cleaved from argininosuccinate through the
argininosuccinase enzyme. This produces arginine which becomes converted to urea and
exported out of the cell, and fumarate which can be recycled to the urea cycle or used in the
citric acid cycle.5,6 For its vital use in human biology, FA has been investigated as a
monomer for creating biomaterials and drugs.
Exploration into the medicinal properties of FA started in the 1950s. An anti-psoriasis
medication was first developed using FA esters. Specifically, dimethyl fumarate (DMF)
contains two methyl end groups and has been shown to help modulate the autoimmune
response during psoriasis flare-ups (Figure 1-1).7 Oral delivery of the drug did not readily
absorb through the gastrointestinal tract but was hydrolyzed into an ester derivative before
entering the circulatory system.1,8 Monomethyl fumarate, an ester form of DMF, was able to
circulate throughout the body and reduce psoriasis (Figure 1-1). The mode of removal of the
fumarate drug was primarily through respiration and a small fraction was through the urinary
and fecal routes.9 The success of DMF treating psoriasis spurred further investigation of
other FA esters for treating the disease. Dimethyl fumarate and diroximel fumarate were
found to help mitigate complications due to multiple sclerosis, and formoterol fumarate
dihydrate was developed into an inhalant for treating chronic obstructive pulmonary disease
and asthma.10,11 Fumaric acid esters are continuing to be explored for its medicinal
properties.
Fumarate-based molecules have been used in industrial applications as well.
Dimethyl fumarate was previously used as a preservative in anti-humidity bags for
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transporting furniture and shoes. In the mid-2000s, cases of contact dermatitis were linked to
skin exposure to DMF in Europe.12,13 Use of DMF as a preservative has recently been
limited. Dibutyl fumarate (DBF) is another fumarate-based polymer containing butylene end
groups and has been used as a plasticizer (Figure 1-1). Specifically, it can be co-polymerized
with other monomers, like vinyl chloride, styrene, acrylate, etc., to prepare coatings,
adhesives, and surface conditioning agents.14 Additionally, DBF has been investigated as an
environmentally friendly plasticizer due to its biodegradable properties in aqueous solutions
and low toxicity to mammalian cells.15–20
2. Fumarate-Based Polymers
Fumarate-based polyesters were first developed 20 years ago and used for biomedical
applications. They were proposed as an injectable biomaterial that could fill defects and help
with tissue repair while avoiding invasive procedures.21 Fumaric acid can be synthesized
using different monomers to create linear polyesters. With multiple unsaturated doubles
bonds in the backbone, fumarate-based polymers are suitable for both thermal and photo
crosslinking methods.22 Multiple types of crosslinkers can be combined with poly fumarates
to control material properties. Depending on the monomer, fumarate can be synthesized to
form a hydrophobic polymer like poly(propylene fumarate) (PPF), a hydrophilic polymer like
oligo(poly(ethylene glycol) fumarate) (OPF), and amphiphilic polymer like poly(propylene
fumarate-co-ethylene glycol) (P(PF-co-EG)) (Figure 1-2). In this work PPF, P(PF-co-EG),
OPF, poly(caprolactone fumarate) (PCLF), and poly(butylene fumarate) (PBF) will be
reviewed as they are the most used fumarate-based polymers in tissue engineering.
2.1 Poly(Propylene Fumarate)
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Poly(propylene fumarate) (PPF) was first discovered in 1988 and has been shown to
have many tissue engineering applications ranging from hard tissue repair (e.g. bone
substitute), soft tissue repair, and controlled-release of biological factors, cells, and drugs.23
Generally, PPF has been shown to have suitable biomaterial characteristics for tissue
engineering. Although there have been multiple ways to synthesize PPF, it has often been
synthesized in a two-step procedure starting with diethyl fumarate (DEF) and 1,2propanediol and in the presence of a catalyst.23–28 The result of the first step is
bis(hydroxypropyl) and ethanol. The second step is a transesterification of
bis(hydroxypropyl) followed by a series of aqueous washes to remove the catalyst and
remove any unreacted monomers as well as drying and solvent removal steps (Figure 1-3).
This method allows for the control of the molecular weight (500-4,000 g/mole) of PPF
through the control of heating and reaction time during the transesterification process.28
Poly(propylene fumarate) polymer is hydrophobic and highly viscous at room
temperature and readily dissolves in chloroform, methylene chloride, tetrahydrofuran,
acetone, alcohol, and ethyl acetate.22 Multiple types of crosslinkers, like poly(ethylene
glycol) dimethacrylate (PEGDMA), poly(ethylene glycol) (PEGDA), dimethyl fumarate
(DMF), N-vinyl pyrrolidone, and poly(propylene fumarate) diacrylate (PPFDA), have been
used to chemically crosslink the polymers into solid materials and control the material
properties of the final scaffold.23,29,30 For example, PPF has been combined with PPFDA and
showed higher mechanical strength compared to other crosslinkers and increased
degradation. This is due to the additional double bond and ester in the PPFDA creating a
tighter polymer network and having additional cleavage sites during degradation.31,32
Furthermore, PPF and crosslinkers have been crosslinked through thermal and photo
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crosslinking methods, making it a versatile material that can be injected into wound sites.33–36
Specifically, PPF and DMF have been combined with the photoinitiator bis(2,4,6trimethylbenzoyl) phenylphosphine oxide (BAPO) and crosslinked with UV light to form
casted or printed constructs.27 Crosslinked PPF creates a hard plastic material that has similar
strength as bone. For instance, crosslinked PPF and DEF materials have an elastic modulus
within the 150-200 MPa range.27
Poly(propylene fumarate) has been used as a scaffold material for a variety of cell
types but has been primarily explored as a bone scaffold material due to its mechanical
properties. Since PPF is made from fumarate and propylene, the degradative byproducts can
be excreted from the body through the urinary system, making it safe for implantation into
the body (Figure 1-2). In vitro cell studies have proven that the PPF scaffold supports
osteoblastic attachment and bone growth, implying cells can migrate onto the scaffold,
attach, and start to replace it with the native extracellular matrix as the scaffold degrades.37–39
Stem cells, specifically marrow stromal cells, also successfully grow on PPF scaffolds and
can be differentiated into different mesenchymal cells, including osteoblasts, through
exogenous factors.40,41 In vivo studies have shown that PPF bone scaffolds have a mild
immunogenic response when implanted, making them an optimal material for medical
devices and drug delivery systems.24
Currently, PPF is being used as material for advanced additive manufacturing and
drug delivery platforms. Innovations in additive manufacturing are making it possible to
create complex three-dimensional (3D) constructs with defined features within the
micrometer scale, enabling the replication of native extracellular matrix organization.
Bioprinting is a type of additive manufacturing technique that extrudes a material in the form
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of a bioink into layers. These layers are then stacked upon themselves to make a 3D
construct. Poly(propylene fumarate) has been investigated as a bioink to print porous
constructs for bone tissue engineering.42–44 Additionally, PPF has been investigated as a
material for use as a versatile drug delivery platforms. One application utilizes PPF as a
conduit that entraps particles, containing the drug to control the release of the drug and
supply a scaffold for tissue regeneration. Specifically, poly(DL-lactic-co-glycolic acid)
(PLGA) microspheres were laden with bone morphogenic protein-2 (BMP2) and encased in
PPF. The release of BMP2 out of the PLGA microspheres was found to be at a rate
proportional to the degradation of PPF and the combination of controlled release of BMP2
and the PPF scaffold were optimal for bone regrowth.45–48 The other platform used for drug
delivery entails loading PPF scaffold solutions or scaffolds with drugs. This method has been
an injectable in situ method for repairing tissue and delivering a drug.49,50 Additionally, this
platform has been employed for 3D bioprinting applications. In one case, a bioink was made
with heparin-loaded gelatin methacrylate, decellularized pericardium, and PPF and then
printed into layers for vascular engineering materials that are antithrombotic.37,51,52 Merging
additive manufacturing, drug delivery, and PPF will allow the creation of a bone scaffold that
can create the biomechanical, biochemical, and extracellular matrix organization that is
necessary to regenerate large defects in bone tissue.
2.2 Poly(Propylene Fumarate-co-Ethylene Glycol)
In an effort to increase the hydrophilicity of PPF, poly(ethylene glycol) has been
synthesized with PPF to make P(PF-co-EG) in 1997 to make an amphiphilic polymer
(Figure 1-2).53–55 Many formations have been derived from the linear block copolymer.
Specifically, PEG units of 570, 800, 1,960, and 5,190 g/mole have been combined with PPF
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(1,570 g/mole) at a 2:1 PEG:PPF molar ratio.56 Formulations containing longer chains of
PEG show greater hydrophilicity. Traditionally, P(PF-co-EG) has been synthesized using a
3-step procedure. The first two steps are identical to synthesizing PPF while the third step
reacted methoxy PEG with PPF under vacuum at 160℃. Purification of the final P(PF-coEG) polymer was done through filtration and precipitation steps followed by drying under
vacuum (Figure 1-4). The final product was either a waxy solid, formulations with less
amount of PEG, or a powder, formulations with more amount of PEG.24,54 The polymer also
contains thermo-sensitive gel properties when dissolved in an aqueous solution and
mechanical properties can be improved through crosslinking methods. Specifically, the
polymer solution is liquid below temperatures of 25℃ and gel above 35℃.56–58 The most
common method for crosslinking P(PF-co-EG) is through thermal crosslinking with a redox
reaction. Ammonium persulfate and N,N,N’,N’-tetramethylethylene diamine, ammonium
persulfate and ascorbic acid, or benzoyl peroxide and N-vinyl pyrrolidinone have been used
to initiate crosslinking of P(PF-co-EG) into solid structures.55,57,58 It was found that the
swelling ratio of crosslinked scaffolds could be reduced by increasing the relative amount of
PPF block. Additionally, the mechanical strength of the scaffolds can be decreased by
increasing the relative amount of PEG.54,55
Poly(propylene fumarate-co-ethylene glycol) has been developed as a
thermoreversible hydrogel platform for delivery cells and bioactive factors to a direct
location in the body. This platform has been shown to support chondrocyte viability and
growth when encapsulated within.24,59 In another study by Suggs and Mikos, P(PF-co-EG)
was used as a carrier for endothelial cells injected subcutaneously in a rat’s back. Results
demonstrated cells embedded in a thermally crosslinked hydrogel and implanted
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subcutaneously in the rat remained viable. Finally, a normal inflammatory and woundhealing response were observed.60 Poly(propylene fumarate-co-ethylene glycol) scaffolds
have also been investigated for bone engineering by modifying the hydrogel to have cell
adhesion ligands. These peptide sequences improved mesenchymal stem cells attachment and
spreading while still retaining the ability to differentiate into osteoblasts.61,62
2.3 Oligo(Poly(Ethylene Glycol) Fumarate)
Since its development in 2001, OPF has been extensively used for musculoskeletal,
nerve, and other soft tissue applications.63 The linear polymer consists of multiple
poly(ethylene glycol) (PEG) monomers linked together by fumarate groups (Figure 1-2).
Traditionally, PEG has been used as a hydrophilic polymer that can be functionalized with
acrylates to make hydrogels for a plethora of biomedical applications. Synthesis of OPF was
first done using a single-step condensation reaction between PEG and fumaryl chloride in the
presence of an acid scavenger, but other methods have been developed to synthesize the
polymer without acid scavengers.63–65 Briefly, varying molar ratios of PEG to fumaryl
chloride (1:0.8, 1:0.9, 1:0.98) were reacted together with an acid scavenger overnight,
followed by solvent evaporation and recrystallization steps in ethyl acetate (Figure 1-5A). A
newer method for creating OPF has been developed that eliminates the use of any acid
scavengers. This method uses nitrogen sparging to mobilize the hydrochloric acid byproducts
into a neutralizing bath. This method reduces the necessity for recrystallization and washing
post-processing steps (Figure 15B).65
The final product at these molar ratios showed that OPF was a solid powder and,
depending on synthesis methods, the powder could be light brown, due to residual acid
scavenger, or white.64,65 Because the reaction is run in an excess of PEG, the OPF molecule
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is terminated with PEG end groups which could be utilized for further modifications.
Specifically, the hydroxyl end groups of the terminal PEGs can be functionalized with
attachment peptides for increased cell attachment.66 Furthermore, the molecular weight of the
precursor PEG determines much of the physical properties and degree of polymerization of
OPF.67 Experiments using PEG ranging from 800-30,000 g/mole have been explored for
synthesizing OPF. However, molecular weights larger than 10,000 g/mole had less chance of
oligomerizing due to steric hindrance of the PEG monomer. It was found that the highest
degree of oligomerization of OPF was with 1,000, 3,400, and 4,600 g/mole PEG, which
resulted in OPF molecular weights of 7,000, 11,610, 12,600 g/mole, respectfully.63
Since OPF contains multiple unsaturated double bonds and is soluble in water, the
polymer can be crosslinked into a network through chemical or photo crosslinking strategies
to form a hydrogel system. Thermo crosslinking was traditionally explored as an injectable
system that supported a minimally invasive procedure.68–71 Ideally, the chemical initiators
would crosslink the OPF at body temperature, 37℃, and within a desired time frame. The
gelation time of the OPF solution depended on PEG molecular weight and initiator
concentration. Ammonium persulfate and ascorbic acid redox initiators were first used with
OPF to form hydrogels. It was found that higher concentrations of initiator were needed to
reduce the gelation time from a matter of hours to minutes but the higher concentrations were
cytotoxic.72,73 Later, PEG diacrylate (PEGDA) was incorporated with the OPF solution and
ammonium persulfate/ascorbic acid solution and significantly reduced the crosslinking
time.74 Due to the cytotoxicity of ammonium persulfate and ascorbic acid, other redox
initiators have been investigated — namely, ammonium persulfate and N,N,N’,N’tetramethylethylenediamine (TEMED) or sodium persulfate with sodium ascorbate and
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magnesium ascorbate-2-phosphate.72,73 Photo crosslinking has also been a successful method
for crosslinking OPF for cell growth, cell encapsulation, and drug delivery applications.
Multiple types of initiators, including Irgacure 819, Irgacure 2959, and Lithium phenyl-2,4,6trimethylbenzoylphosphinate (LAP), have been used to make hydrogels.75–79 Concentrations
ranging from 0.05%-0.3% (w/w) of Irgacure 2959 were found to be crosslinked within a time
frame of 10-40 minutes under UV exposure (365 nm). The more water soluble photoinitiator
LAP was found to reduce the UV exposure time for crosslinking OPF and PEGDA hydrogels
and was less cytotoxic.77,78 Finally, the addition of crosslinkers, like PEGDA, accelerated the
photocrosslinking.
Mechanical properties of crosslinked OPF hydrogels were highly dependent on the
molecular weight of the PEG monomer and the degree of oligomerization of OPF.
Specifically, lower molecular weight PEG and higher oligomerized OPF increased tensile
and compression strength.70,71,74 This phenomenon is attributed to the mesh size of the
polymer network increasing when PEG molecular weight increases and few fumarate groups
are available for crosslinking.63,74,80,81 Additionally, degradations studies of crosslinked OPF
hydrogels showed that crosslinking density influenced in vivo biocompatibility. In
subcutaneous rabbit studies, OPF8K degraded faster causing a higher number of
inflammatory cells to surround the fragmented OPF hydrogel, while OPF1K degraded slower
reducing the inflammatory response.71
Oligo(poly(ethylene glycol) fumarate was first developed for cartilage and bone
regeneration and was shown to successfully support in vitro cell growth of native cells on
and within hydrogels as well as differentiation of bone marrow-derived stem cells into
chondrocytes and osteoblasts. Through the addition of attachment peptides, the hydrogel
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platform also showed minimal inflammatory activation while promoting cell migration and
growth in the scaffolding during in vivo studies.71,80,82 More advanced OPF platforms have
started incorporating timed-release growth factors or bioactive particles components to create
an environment that promotes either cartilage or bone tissue. Such growth factors like
transforming growth factor-β1 (TGF-β1) have been shown to promote cartilage tissue growth
through the production of glycosaminoglycans (GAG), collagen II, and aggrecan.70,83–85
Bioactive particles have also been incorporated into the hydrogel matrix to improve bone
formation. Calcium phosphate was first incorporated in OPF hydrogels to help stimulate
bone remodeling in vivo studies.86–89
Furthermore, OPF has been investigated as a biomaterial for nerve conduits to
regenerate nerves. Specifically, electrically charged OPF hydrogels have been shown to
improve nerve repair.90,91 Although very little research has been performed on anionic OPF
hydrogels, there have been several studies using cationic moieties in OPF hydrogels.
Dadsetan et al. created a positively charged hydrogel platform with OPF and [2(methacyloyloxy)ethyl]-trimethylammonium chloride (MAETAC) to demonstrate that
positively charged OPF (OPF+) hydrogels had a dose-dependent effect on neurite
outgrowth.92–94 Specifically, OPF+ containing 400 mM and 600 mM of MAETAC supported
more outgrowth of dorsal root ganglia, attachment of Schwann cells, and neurite myelination
compared to concentrations lower than 400 mM and 800 mM. Moreover, multi-channel
cylindrical OPF+ conduits implanted in the transected spinal cord of rats resulted in better
tissue interaction and integration to the point of filling the transected gap and structural and
functional restoration. It was also found that these conduits reduced the amount of spinal cyst
and scar tissue formation.95,96 Other tissue engineering and regenerative applications have
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been explored using OPF. Oligo(poly(ethylene glycol) fumarate) has been explored as a
biomaterial for pigment epithelial cell delivery for lens regeneration as well as ligament
scaffolding for ligament regeneration.97–100 Finally, conductive OPF polymers have been
investigated as a biomaterial that can reestablish the electrical connection of damaged
cardiomyocytes and promote neovascularization.101,102
2.4 Poly(Caprolactone Fumarate)
Poly(caprolactone) (PCL) is an FDA approved hydrophobic polymer that is widely
used as a biomaterial for sutures and drug delivery applications.103,104 This synthetic polymer
is one of the most studied and used biomaterials for biomedical applications.
Poly(caprolactone fumarate)’s molecular weight and degradation rate can be used to control
the polymer’s physicochemical properties.105 Specifically, PCL usually degrades over 2-4
years which is a significant time frame for tissue engineering applications.103,106,107
Therefore, copolymerization with fumarates has been developed to create PCLF, a faster
degrading aliphatic polymer.108,109 The addition of the unsaturated double bonds and the
flexibility of the polymer’s backbone due to the long caprolactone chains allows PCLF to
self-crosslink without the addition of crosslinkers, ideal for in situ crosslinking which is
attractive for tissue engineering and injectable delivery systems.108,109 Poly(caprolactone
fumarate) was first reported synthesized in 2005 through a one-step polycondensation
polymerization of PCL diols with fumaryl chloride in the presence of an acid scavenger.
Briefly, PCL diols were dissolved in dichloromethane and fumaryl chloride, and an acid
scavenger was added dropwise to the reaction. The final product was then post-processed
through precipitation in petroleum ether and dried under vacuum (Figure 1-6). Varying
molecular weights of PCL (530, 1,250, 2,000 g/mole) were shown to form PCLF and the
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final product was in the form of wax- or past-like texture. This method by Jabbari et al. has
been widely adopted.108–110 Further adaptions to the type of acid scavenger were shown to
improve the coloration of the final polymer as well as a two-step synthesis process utilizing a
ring-opening step of caprolactone followed by the condensation polymerization of PCL with
fumaryl chloride, which was shown to reduce the cytotoxic byproduct of diethylene glycol.
110–112

It was found that the molecular weight of the precursor PCL affected the physical
properties of the PCLF. As the molecular weight of PCL increased, the crystallinity and
melting point also increased.39,109,113 A similar trend was found for the thermal stability of
PCLF. As PCL molecular weight increased the degradation onset temperature increased
making PCLF with higher molecular weight PCL more thermally stable.114 Furthermore,
Wang et al. showed the PCLF did not start hydrolytically degrading until week 20 at 37℃ in
PBS, despite the molecular weight of PCL monomer. It was not until week 71 that the higher
molecular weight PCLF was mostly degraded.114 As a biomaterial for tissue engineering, the
incorporation of fumarate in PCLF reduced the degradation time of traditional PCL.
Since PCLF can crosslink, thermal and photo crosslinking strategies have been
investigated as methods to create scaffolds. Like other thermal crosslinking methods, a
crosslinker and chemical initiator was combined with PCLF. Crosslinkers investigated have
been methyl methacrylate, PEGDA, and N-vinyl pyrrolidone with chemical initiators benzoyl
peroxide and N-dimethyl toluidine.109 Temperatures within the body temperature (37-40℃)
were able to crosslink PCLF solutions.108,115 Additionally, composites PCLF scaffolds using
hydroxyapatite particles resulted in crosslinking with higher temperatures of 90℃ and an
additional post-curing step at 120℃.116 The more common method of crosslinking PCLF has
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been photocrosslinking because it is simple, requires less time, and circumvents the use of
several toxic monomers and initiators needed for thermocrosslinking.67 Similar to PPF
photocrosslinking strategies, PCLF has been combined with multiple photoinitiators. The
primary initiator used has been bisacylphosphinoxide (BAPO). Varying concentrations of
BAPO were tested to determine the degree of crosslinking. These tests showed that the gel
fraction increased and the swelling ratio decreased with the increase in BAPO concentration.
Additionally, the PCL molecular weight affected the swelling ratio with the highest
molecular weight PCL causing the highest swelling ratio of PCLF.109 In an attempt to use a
more biocompatible photoinitiator system, Sharifi et al. used camphorquinone and N, N’diemthyl aminoethylemethacrylate and concluded that PCLF scaffolds could be formed with
blue light, rather than UV light, and shorter crosslinking times (~4 minutes), compared to an
hour of UV exposure.117,118
Poly(caprolactone fumarate) scaffolds have been primarily used in nerve and bone
tissue engineering applications, with some studies applying PCLF to ligament, cartilage, and
blood vessel engineering. Nerve conduits have been developed using PCLF and have shown
success in growing and repairing nerves. Initially, PCLF conduits attached to nerves and
supported a high number of myelinated axons through the cylinder with minimal fibrosis
after 6 and 17 weeks.114 Then, multi-channeled nerve conduits that delivered Schwann cells
were used as a conduit for a transected rat spinal cord. Results show that significant growth
of axons in random directions was observed within the channels. The high compressive
moduli of the PCLF did promote the formation of cyst and scar tissue in the rostral and
caudal interface of the conduit with the spinal cord.95 Furthermore, PCLF has been
investigated as a scaffolding material for growing fully functional nerve grafts. In order to
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make nerve grafts researchers have created charged PCLF scaffolds using polypyrrole with
five different anions and conductive carbon nanotubes.94,119–121 It was found that the increase
in conductive capacity improved the proliferation, neurite outgrowth, neuronal
differentiation, and the formation of synapse-like intercellular connections of PC-12.120–122
As a scaffold for bone regeneration, PCLF has a lower modulus for loading bearing
bone. Therefore, a lot of research has aimed at creating composite materials using PCLF and
bioceramics. It was shown that incorporating hydroxyapatite nanoparticles increased the
compressive modulus of PCLF with lower molecular weight PCL on an order of 3.5x with
the addition of 30% of hydroxyapatite nanoparticles but did not improve the compressive
strength of PCLF with higher molecular weight PCL. The hydroxyapatite nanoparticles
improved bone marrow stem cell attachment and proliferation.116,123 Moreover, PCLF was
used as a coating solution into porous hydroxyapatite scaffolds. This method increased the
overall mechanical strength of the scaffold but PCLF had little effect on osteoblast
attachments as they already liked to attach to the hydroxyapatite scaffold and possibly
inhibited cell attachment and proliferation because of PCLF hydrophobic properties.124–127
Woven PCLF fibers with poly(ethylene terephthalate) (PET) were investigated as a
ligamentous scaffold for anterior cruciate ligament (ACL) repair. Mechanical testing of
hybrid scaffolds resulted in a failure load of 72 N which is far less than the native ACL
failure load of 353 N.128 In vivo studies showed that after 8 weeks the mean failure loads
decreased for PCLF-PET scaffolds and was disintegrated into pieces. These pieces resulted
in a dense inflammatory reaction making PCLF not an ideal candidate for ligament
engineering.128 Additionally, PCLF has been investigated as cartilage and soft tissue
scaffolding. It was shown that PCLF supports cell growth and production of key
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cartilaginous markers but due to the hydrophobic nature of the polymer, growth factors could
not be loaded into the scaffold to improve tissue formation.129 The combination of PCLF and
growth factor-loaded PLGA microspheres delivered the growth factors in a controlled
manner and resulted in infiltration of tissues and neovascularization into the scaffold.130
2.5 Poly(Butylene Fumarate)
Poly(butylene fumarate) is a linear polyester that has similar properties to PPF. Like
PPF, PBF is a hydrophobic polymer that contains unsaturated double bonds and is
hydrolytically biodegraded, but unlike PPF, it can be chemically engineered to have different
material properties through manipulation of its butylene group. In early 2010, two forms of
PBF were first reported and they were synthesized with 1,3-butanediol or 1,4-butanediol
(Figure 1-2).131–133 The linear form of PBF was developed into a block copolymer with
poly(butylene succinate) and poly(butylene maleate).133–136 Multiple synthesis methods have
been used to make PBF. One method used a ring-opening strategy starting with maleic
anhydride where maleic anhydride, 1,3-butanediol, and an acid scavenger were heated
together to 250℃ for 3 hours. This synthesis process starts by converting maleic anhydride to
maleic acid. Followed by the transformation of maleic acid into fumaric acid. The
transesterification of fumaric acid and 1,3-butanediol then proceeds. The final crude polymer
was post-processed by washing and drying steps (Figure 1-7).132,133,136 The other synthesis
methods used a two-step, esterification, and polycondensation, process. Briefly, fumaric acid,
1,4-butanediol, an acid scavenger, and a free radical inhibitor were reacted together at 150℃
until all the water byproduct was removed. The first step produced PBF-diol which is then
put under pressure (5-15 Pa) and polymerized to create specific molecular weights of PBF
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(Figure 1-7).131 PBF is a viscous brownish material that is highly tactile when synthesized
with 1,3-butanediol or a solid material if synthesized with 1,4-butanediol.
Since the PBF contains unsaturated double bonds, it has been developed into a
crosslinkable material. Specifically, the poly(1,3-butylene fumarate) (1,3-PBF) has been
developed into a photocrosslinkable material using BAPO and UV light.132,133 The
crosslinked 1,3-PBF scaffolds have shown similar mechanical properties as PPF and were
appropriate for orthopedic applications. It was concluded that the addition of the methylene
unit (-CH2) also increased the degradation of 1,3-PBF relative to PPF.132 The poly(1,4butylene fumarate) (1,4-PBF) was found to be a crystalline polymer forming solids at room
temperature. It was found that the tensile and flexural strength of 1,4-PBF were 41.0 MPa
and 26.7 MPA.131
Poly(butylene fumarate) has not been thoroughly investigated as a crosslinkable
biomaterial for biomedical applications, which offers an opportunity for further development
as a tissue engineering polymer. Current uses of PBF for biomedical applications have
investigated poly(1,3-butylene fumarate) (1,3-PBF) as a biodegradable polymer for bone
engineering. It was found that 1,3-PBF scaffolds were not cytotoxic to bone marrow derived
mesenchymal stem cells and supported cell attachment and differentiation into osteoblasts.132
Additionally, 1,3-PBF has been used to create electrospun mats that have potential as a
scaffolding material and drug delivery system.133
3. Conclusion
Fumarates are a versatile biomolecule that the human body has utilized for creating
energy and expelling waste. Scientists and engineers have discovered the medicinal and
industrial properties of fumarates but more recently have created polymers useful for
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biomedical applications. Recent developments in fumarate-based polymers have created a
class of polymers, PPF, P(PF-co-EG), OPF, PCLF, and PBF, with ranging material
properties. Their past and present applications in musculoskeletal, nerve, and other tissue
applications have shown these biomaterials as useful biodegradable scaffolds capable of drug
delivery. As tissue engineering progresses, fumarate-based polymers can be used for solving
future challenges of growing complex tissues, modeling cell environments, and developing
new drugs and treatments that will be used to progress the regenerative medicine field.
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Figures

Figure 1-1. Molecular structures of fumarate-based small molecules. Fumaric acid is a
vitally important molecular found in the human body. Fumaric acid esters, dimethyl
fumarate, diethyl fumarate, diroximel fumarate, are pharmaceuticals that are cleaved within
the body to create the pharmacologically active monomethyl fumarate. Dibutyl fumarate is
an industrial plasticizer.
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Figure 1-2. Molecular structure of fumarate-based polymers used in tissue engineering,
regenerative medicine, and drug delivery.

20

Figure 1-3. Synthesis of PPF in a two-step polycondensation method. Step one reacts DMF
and propylene glycol to make short oligomers of bis(hydroxypropyl) fumarate. The second
step is a transesterification process that creates long chains of PPF. Adapted from (28)

21

Figure 1-4. Synthesis of P(PF-co-EG) in a three-step process. The first two steps are
identical to synthesizing PPF. The third step is a transesterification of PEG with PPF.
Adapted from (56)
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Figure 1-5. Two methods for synthesizing OPF. (A) is a single-step condensation reaction
that uses an acid scavenger to capture hydrochloric acid byproducts. (B) is another singlestep condensation reaction but uses inert gas sparging to mobilize hydrochloric acid
byproduct into a base bath. Adapted from (65)
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Figure 1-6. One-step polycondensation reaction for synthesizing PCLF. Varying molecular
weights of PCL reacted with fumaryl chloride to create varying molecular weights of PCLF.
Adapted from (108)
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Figure 1-7. Two synthesis strategies used to synthesize PBF. Ring-Opening synthesis has
been used to create 1,3-PBF. The two-step synthesis uses an esterification step (a) to create
1,4-PBF (PBF-Diol). Followed by a polycondensation step (b) to create long chains of 1,4PBF. Adapted from (133) and (131)
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Chapter 2
Specific Aims
Objective
The tissue engineering paradigm uses three factors, biomaterials, growth and soluble
factors, and cells, to design and replicate complex tissue systems for pharmaceuticals,
medical devices, and regenerative medicine development. Natural and synthetic biomaterials
are typically used as scaffolding for cells to attach, proliferate, and grow into specific types
of tissue. The chemical and mechanical properties of the scaffolds are a factor that can be
used to direct cells into specific tissue types. For instance, soft tissue highly prefers soft
scaffolds, while hard tissue prefers porous, stiff scaffolds.
Traditional culturing methods on tissue culture polystyrene surfaces have been shown
to alter or direct the aortic valvular interstitial cell (VIC) phenotype. Specifically, it was
found that positively charged self-assembled monolayers can direct VICs to become
osteoblastic-like, the major phenotype that leads to aortic stenosis. The fumarate-based
polymer oligo(poly(ethylene glycol) fumarate) (OPF) is a hydrophilic polymer with multiple
unsaturated bonds useful for crosslinking or functionalizing. This makes OPF advantageous
for making a cell platform that mimics the soft tissue of the aortic heart valve leaflets and
exposes VICs to a three-dimensional (3D) environment. Therefore, a positively charged OPF
hydrogel has been investigated to determine if positively charged environments stimulate
VICs to become osteoblastic-like.
Current research is investigating how to make composite scaffolds that replicate the
biomechanical, biochemical, and material organizations of the bone-ligament (BL) interface.
Specifically, the BL milieu transitions from a hard crystalline bone phase through a
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fibrocartilaginous enthesis into an elastic fibrous ligament phase. Poly(propylene fumarate)
(PPF), another fumarate-based polymer, has been used extensively as a biomaterial for
growing bone. Similar to PPF, poly(butylene fumarate) (PBF) is a hydrophobic polymer that
also contains multiple unsaturated bonds but, unlike PPF, PBF has the ability to be
chemically engineered to have varying material properties by using different conformations
of butylene. The different forms of PBF can be photocrosslinked into constructs with varying
mechanical and chemical properties which potentially can be useful for creating the BL
interface. Therefore, poly(1,2-butylene fumarate) (1,2-PBF) and poly(1,3-butylene fumarate)
(1,3-PBF) has been investigated as polymers used for creating the BL interface.
In this work, fumarate-based biomaterials have been investigated as soft and hard
biomaterials for tissue engineering. We showed that both OPF and PBF (1,2-PBF and 1,3PBF) can be synthesized using an acid-free synthesis method developed in our lab.
Additionally, OPF hydrogels have been investigated as a 3D culturing platform for testing
positively charged 3D environments on VICs. Finally, two variations of PBF, 1,2- and 1,3PBF, have been synthesized and characterized.
Specific Aims
The following specific aims throughout this project:
Specific Aim 1: Fabricate a synthetic OPF-based hydrogel with tunable positively charged
densities.
It is hypothesized that a polymer concentration of 25 wt% of OPF and crosslinker will
form hydrogels with mechanical properties similar to soft tissue and have the ability to
support varying concentrations of charged monomers up to a concentration of 400 mM.
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Specific Aim 2: Characterize the viability of the valvular interstitial cells (VICs) when
exposed to the positively charged OPF hydrogel solution, during UV encapsulation, and in
culture through fluorescent assay analysis.
It is hypothesized that VICs will be encapsulated in the positively charged
environment and the hydrogels with higher charge density will cause VICs to present a
diseased osteoblastic-like phenotype.
Specific Aim 3: Investigate the chemical and material properties of 1,2-PBF and 1,3-PBF
polymers and crosslinked films.
It is hypothesized that 1,3-PBF will have properties similar to bone tissue and 1,2PBF will have properties useful for growing mineralized fibrocartilage tissue.
Broader Impact
Upon completion of this work, two fumarate-based polymers will have been applied
to two different tissue engineering applications. First, using OPF to make a hydrogel system
for encapsulating and growing VICs will create a 3D cell culture platform for valvular
engineering. Incorporating positively charged end groups into the hydrogel network proves
the feasibility of using charged environments for further cell-material interactions studies.
This will help to develop smarter materials for medical applications. Second, PBF will be
investigated as a stiff biomaterial. Two variations of PBF will have been synthesized and
characterized. Specifically, 1,2-PBF has never been synthesized and investigated as a
biomaterial for tissue engineering and will be considered as a new biomaterial for
engineering the biomechanical BL interface. Potentially, 1,2-PBF and 1,3-PBF will have
application in developing a BLB construct for ligament repairs. Further research and
application of fumarate-based polymers show their utility not only in the tissue engineering
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and regenerative medicine field but also as biomaterials for additive manufacturing
applications, cell and organ modeling, and medical device development.
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Abstract
The macromolecule oligo(poly(ethylene glycol) fumarate) (OPF) exhibits promising
attributes for creating suitable three-dimensional hydrogel environments to study cell
behavior, deliver therapeutics, and serve as a degradable, nonfouling material. However,
traditional synthesis techniques are time consuming, contain salt contaminants, and generate
significant waste. These issues have been overcome with an alternative, one-pot approach
that utilizes inert gas sparging. Departing from previous synthetic schemes that require acid
scavengers, inert gas sparging removes byproducts in situ, eliminating significant filtration
and postprocessing steps, while allowing a more uniform product. Characterized by nuclear
magnetic resonance, gel permeation chromatography, and differential scanning calorimetry,
nitrogen sparge synthesis yields an OPF product with greater polymer length than traditional
acid scavenger synthesis methods. Furthermore, nitrogen-sparged OPF readily crosslinks
using either ultraviolet or thermal initiator methods with or without the addition of short-chain
diacrylate units, allowing for greater tunability in hydrogel properties with little to no
cytotoxicity. Overall, inert gas sparging provides a longer chain and cleaner polymer product
for hydrogel material studies while maintaining degradable characteristics.
Keywords: oligo(poly(ethylene glycol) fumarate), OPF, polyethylene glycol, polymers,
hydrogel
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Impact Statement
Using nitrogen sparging, we have demonstrated that oligo(poly(ethylene glycol)
fumarate) (OPF) can be produced with decreased postprocessing, increased product
purity, greater oligomerization, and cell viability. These properties lead to greater
tunability in mechanical properties and a more versatile hydrogel for biomedical
applications. The simplification of synthesis and elimination of impurities will expand the
utility of OPF as a degradable hydrogel for cell culture, tissue engineering, regenerative
medicine, and therapeutic delivery, among other applications.
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Introduction
Oligo(poly(ethylene glycol) fumarate) (OPF) has been extensively investigated as a
biodegradable hydrogel for use in tissue-engineered scaffolds and drug delivery.1–13 The stepgrowth polymerization of polyethylene glycol (PEG) and fumaryl chloride (FuCl) produces
a linear polyester with hydrochloric acid (HCl) byproducts. The resulting oligomer consists
of a repeating scheme of PEG and fumarate, which can be chemically crosslinked into a
nonfouling hydrogel (Figure 3-1). The ability of OPF to undergo hydrolytic degradation
through ester hydrolysis gives OPF greater utility over previous polyethylene glycol
diacrylate (PEGDA) hydrogels.14–17 In addition, the physical properties of OPF can be easily
tailored by changing the PEG length.1,18 Due to the presence of unsaturated double bonds,
functionalization of the oligomer backbone can be achieved before or during crosslinking
with the incorporation of short-chain molecules.4,10 Overall, these factors make OPF a
desirable synthetic polymer for multiple applications.
Developed by Jo et al., OPF synthesis has not been significantly modified since its
inception.1,2,19 However, several groups have reported issues with removal of HCl byproducts
affecting crosslinking efficiency and cell viability.20–22 To trap HCl, groups have used acid
scavengers such as triethylamine (TEA), potassium carbonate, and sodium hydroxide.16,23–28
However, batch-to-batch inconsistencies in polymer product are common due to inefficient
removal of insoluble HCl-acid scavenger salts.22
Common in waste treatment and manufacturing procedures, sparging is a fast and
efficient method easily introduced into the processing environment.29–33 By bubbling a
chemically inert gas such as nitrogen through a liquid, sparging removes low boiling-point
solutes in real-time.32,33 Furthermore, the introduction of compressed gas into the system
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serves as a heat sync through adiabatic expansion, maintaining the low temperatures required
for efficient step-growth polycondensation.34 Through the introduction of gas sparging, we
have developed a one-pot, straightforward, and improved method for the production of OPF
while simultaneously eliminating the complications of acid removal, filtration, and
postprocessing.
Materials and Methods
Reagents and chemicals
PEG (Mn 4600), FuCl, ascorbic acid (AA), Irgacure 2959, trimethylamine, PEGDA
(Mn 575), deuterated chloroform, and tetrahydrofuran were purchased from Sigma-Aldrich.
Ammonium persulfate (APS; ACS grade) and ethanol along with cell culture reagents,
Dulbecco’s minimum essential growth medium (DMEM), fetal bovine serum (FBS),
phosphate-buffered

saline

(PBS),

penicillin–streptomycin,

fungizone,

trypsin-

ethylenediaminetetraacetic acid (EDTA), and live/dead cell viability kit were purchased from
ThermoFisher Scientific. Dichloromethane (DCM), ethyl ether, ethyl acetate, anhydrous
toluene (99.8%), and sodium hydroxide were purchased from EMD Millipore.
OPF synthesis
PEG drying. PEG was dried by azeotropic distillation before use as previously
described.2 In brief, 100 g of PEG was added to 200 mL of toluene. At least 150 mL of toluene
and residual water were distilled off at 200°C. Toluene was removed on a rotary evaporator
followed by drying in vaccuo overnight. Dried PEG was stored in a desiccator until used.
OPF oligomer synthesis—TEA-OPF. TEA-OPF was prepared according to
previously described methods.1,2 In brief, dried PEG (100 g) was dissolved in 700 mL of DCM
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in a 1 L three-neck round bottom flask set in an ice bath (Figure 3-1A). Air was removed and
replaced with a nitrogen environment. Using molar ratios of 1:0.9 PEG to FuCl and 1:2 FuCl
to TEA, FuCl and TEA were dissolved in 60 mL DCM in separate addition funnels and
simultaneously added dropwise to PEG solution over 4 h. The reaction was stirred vigorously.
Upon complete addition of FuCl and TEA, the reaction mixture was continued over an ice
bath overnight, followed by solvent removal in vacuo. The product was subsequently
dissolved in warm ethyl acetate, chilled (-2°C) to recrystallize OPF and filtered to remove
TEA-HCl salts (3x). After the final collection, the OPF was washed with ethyl ether and fully
dried under reduced pressure overnight.
OPF oligomer synthesis—nitrogen sparging. Dried PEG (100 g) was dissolved in 700
mL DCM in a three-neck round bottom flask with a stir bar and nitrogen environment.
Sparging with nitrogen was introduced through central arm with a 24/40 adaptor fitted with
a fine-fritted gas dispersion tip and forced out through 90° flow control adapter into a
secondary vessel containing 10 wt% sodium hydroxide in ethanol (Figure 3-1B). FuCl was
dissolved in 60 mL DCM at a molar ratio of 1:0.9 PEG to FuCl and added dropwise to the
PEG solution over 4 h with vigorous stirring. Upon complete addition of FuCl to PEG
solution, DCM was added to the reaction mixture to bring the volume back up to 700 mL.
The reaction was allowed to progress overnight with sparging followed by solvent removal
in vacuo.
OPF characterization
OPF structure. OPF products were characterized by hydrogen nuclear magnetic
resonance (1H NMR) 300M Hz (Bruker Avance III 300; TopSpin V3.5) in deuterated
chloroform. Peaks were assigned to confirm the hydrogen binding environment. The degree
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of polymerization was assessed through peak integration comparing olefin (6.87 ppm) and
PEG (3.38–3.85 ppm) functional groups.
Molecular weight and oligomerization. Molecular weight of OPF was determined
through gel permeation chromatography (GPC). Styragel HR 4 + 4E, 7.8 · 300 mm
(WAT044225 and WAT044240) columns were used to elute the samples at a 1 mL/min flow
rate on an Agilent 1100 Series high-performance liquid chromatography system (Hewlett
Packard, RID G1362A; Chemstation B.04.01). Four to five samples of 3 mg were run in 1
mL of tetrahydrofuran. Sample weight-average (Mw) and number-average molecular weights
(Mn) were calculated compared to PEG standards (PL2070-194, 440, 600, 1080, 1470, 4100,
7100, 12,600, 23,600; Polymer Laboratories/Agilent Technologies). The degree of
oligomerization (Xn) was determined using Equation (1):

𝑋! =

"!,#$%
"!,$&'

,

(1)

here, Mn, OPF and Mn, PEG represent the number-average molecular weight (Mn) of OPF,
and monomeric PEG as determined by GPC.
Changes in molecular weight over time were measured by removing a small volume
(1 mL) of OPF product from both TEA-OPF and nitrogen-sparged OPF (N2-OPF) synthesis
reaction vessels over the initial 14 h of synthesis in parallel reactions. Solvent was removed
in vacuo and 3 mg of product were suspended in 1 mL tetrahydrofuran. Refractive index
intensity was normalized to the highest peak of the eluted product.
Fluorescent byproduct. Fluorescence of the polymer product was detected during GPC
through the use of a fluorescence detector (Hewlett Packard, FLD G1321A, Ex 250 nm, Em
410 nm) upstream of the refractive index detector; retention time difference 1 min.
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Melting temperature and crystallinity. Differential scanning calorimetry (DSC; TA
instruments model 2920, Netzsch Proteus) was carried out to determine the crystallinity and
melting properties of OPF. Samples were analyzed at a heating rate of 10°C/min from 0°C to
70°C. Melting temperature and the heat of fusion, D Hm (cal/g), were obtained from the
thermograms. The percent crystallinity (X) of OPF was determined from the following
equation:

𝑋=

# %(
∗
# %(

× 100,

(2)

here, H*m, is the theoretical heat of fusion of 100% crystalline PEG (49 cal/g).35
Percent yield. Percent yield was calculated by weighing the product recovered from
the reaction and dividing it by the weight of reagents originally added.

% Yield =

&'()*+ ,-. /(012 345678+
&'()*+ -9:;&'()*+ .7<14=2 8*254(6'

∶

(3)

Characterization of crosslinked OPF hydrogels
Crosslinking of OPF. OPF hydrogel products were crosslinked with and without
PEGDA (Sigma Aldrich). The ultraviolet (UV) crosslinked formulations were as follows:
25% (wt%) OPF, 0.5% Irgacure 2959 initiator, 74.5% deionized water or 16.5% OPF, 8.5%
PEGDA, 0.5% Irgacure 2959 initiator, and 74.5% deionized water. UV formulations were
exposed to 365 nm UV light in a CL-1000 lightbox (UltraViolet Products, UVP) for 15 min.
The thermally crosslinked hydrogels had the same formulations stated above, except that
17.6 · 10-6 wt% (0.1 mM) AA with 22.8 · 10-6 wt% (0.1 mM) APS was added in place of
Irgacure 2959. Polymer solutions (1 mL) were transferred to syringe molds before
crosslinking.21 Thermally initiated formulations were placed in the incubator (37°C) for 15
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min to form hydrogels. Final products were dried overnight at room temperature before being
placed in the vacuum oven for 24 h.
Swell ratio and sol fraction. Hydrogels were weighed after drying in a vacuum oven
to measure the initial mass of polymer (Wi). Hydrogels were then soaked in 5 mL of
deionized water and allowed to swell. After 4 days, the maximum swollen weight (Ws) was
recorded. Swollen gels were then removed from water and redried in the vacuum oven for 48
h before being weighed to measure the final dry weight (Wd). The swelling ratio was
calculated by subtracting the dry weight (Wd) from the wet weight (Ws), then dividing by the
final dry weight (Wd) [Eq. (4)]. Sol fraction was calculated taking the initial dry weight (Wi)
minus the final dry weight (Wd) divided by the initial dry weight (Wi) [Eq. (5)]. Sample size
of six hydrogels was tested for swelling ratio and sol fraction.

𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑖𝑜 =
𝑆𝑜𝑙 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =

>* ?>+
>+

>, ?>+
>,

∶

∶

(4)
(5)

Hydrogel elasticity. Hydrogel samples of height to width of 2:1 (diameter = 5 mm)
were fabricated for compression testing on an mechanical testing system (MTS) (Chatillon
TCD 200; Wagner Instruments, Greenwich, CT, USA). Before testing, hydrogels were
swollen in deionized (DI) water for 12 h in ambient conditions. Compression testing was run
on an unclosed platform using flat platen with a crosshead speed of 5 mm/min. Load and
displacement was recorded until failure, in which the Young’s modulus was determined by
calculating the stress versus strain curves and determining the slope of the elastic region.
Cytotoxicity analysis
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NIH/3T3 cells were purchased from ATCC (CRL-1658) and cultured in DMEM
medium supplemented with 10% FBS and 1% penicillin–streptomycin and fungizone and
maintained at 37°C with 5% carbon dioxide. Culture medium was changed every 2 days.
In vitro cytotoxicity was investigated using live/dead viability cytotoxicity kit. Cells
were enzymatically removed (0.25% trypsin-EDTA), seeded in 24-well plates at 40,000
cells/cm2. Following 24-h attachment and incubation, the cells were treated by adding 500 μL
of 25% (wt%) hydrogel solutions dissolved in growth media with and without thermal
crosslinking initiators (0.1 mM AA/APS) and co-polymer PEGDA (16.5% OPF and 8.5%
PEGDA). After a 15 min incubation, 1 mL of additional media was added to each well. After
an additional 24 h, cells were washed 3x with PBS and stained with dye solutions according
to manufacturer’s instructions. In brief, 4 mM ethidium homodimer-1 and 2 mM calcein AM
were reconstituted in growth media. Five hundred microliters of dye solution was added to
each sample followed by a 45 min incubation. Cells were imaged using confocal microscopy
(Olympus IX81; live: ex 488 nm/em BA505–525 nm, dead: ex 543 nm/em 560–660 nm) at a
40x magnification. Control samples consisted of living cells, with media changes during
solution exchange procedures, and dead controls incubated with 70% ethanol for 30 min
before assay.
Statistics
All groups were compared in GraphPad Prism 6 starting with a one-way analysis of
variance with 95% confidence interval. If significance was found, then a two-way t-test was
used to determine statistical differences between treatments. Sample sizes equaled three
unless otherwise noted.
Experiment

53

Physical characterization
Nitrogen sparging technique exhibits visual and physical differences when compared
to the TEA acid scavenger method. N2-OPF appeared to be whiter than TEA-OPF,
comparable to the PEG (Mw 4600) precursor (Figure 3-2). TEA-OPF had a light brown
coloration to it even after post-processing washes and precipitations, indicative of trace
amount of HCl salts within the polymer.1 After N2-OPF went through the final drying stage,
it appeared to be clumped due to intermolecular forces, while TEA-OPF had a fine grain
consistency because of salt contamination. Furthermore, it was observed that TEA-OPF
dissolved into aqueous solutions easier than the N2-OPF.
Increased oligomerization of OPF utilizing nitrogen sparging methods
Proton NMR of TEA-OPF and N2-OPF schemes both show the formation of an ester
bond at 4.33 ppm corresponding to the formation of PEG/fumarate oligomers. A shift in
fumarate olefin signal from 7.87 ppm to 6.87 ppm also denotes attachment of FuCl to PEG
(Figure 3-3).36 DSC revealed no significant difference between the Tm and crystallinity of
N2-OPF (60.7 – 0.4°C and 64.1% – 2.1%) and TEA-OPF (60.3 – 1.3°C and 58.3% – 3.4%;
Table 3-1). However, the ratio of PEG hydroxyl end groups (3.01 ppm) to monomer units
was lower in N2-OPF compared to TEA- OPF indicating increased oligomerization.
Utilizing size exclusion chromatography to determine N2-OPF molecular weight (Mw
= 17,271 – 3632) and degree of polymerization (Xn = 3.9 – 0.8) confirmed significant increases in OPF oligomerization over TEA-OPF (Mw = 10,891 – 1368, Xn = 1.8 – 0.2; Table
3-1 and Figs. 3-4A and 3-5A, B).
Furthermore, N2-OPF had a significantly lower polydispersity index 1.3 – 0.06
compared to TEA-OPF 1.4 – 0.04, indicating a more homogeneous product (Table 3-1 and
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Figure 3-4A). OPF product removed during both reactions shows the difference in rate of
oligomerization during TEA-OPF and N2-OPF processing (Figure 3-5). However,
fluorescent analysis of eluted TEA-OPF revealed a fluorescent molecule as- sociated with the
elution of TEA-OPF oligomers that is absent from N2-OPF (Figure 3-4B).
Characteristics of crosslinked hydrogels
Using the thermal initiator AA/APS, N2-OPF crosslinked by itself and had a
significantly higher swell ratio than all other groups (Figure 3-6). However, when
crosslinked in the presence of PEGDA, there was no difference in water up-take between
TEA-OPF and N2-OPF hydrogels. Using UV initiation, N2-OPF with PEGDA had a
significantly lower sol fraction than UV-initiated N2-OPF without PEGDA but no
comparison could be made with TEA-OPF as it would not crosslink using the UV initiator
even with the addition of PEGDA (Figure 3-6). Furthermore, TEA-OPF by itself did not
crosslink with either UV or thermal crosslinking methods, while N2-OPF crosslinked under
all conditions (Figure 3-6).
Compressive modulus of the OPF varied in range from 7.32 – 1.39 to 189.23 – 56.04
KPa, depending on the synthesis and crosslinking method, as well as presence of PEGDA
linker (Mn 575; Figure 3-7). TEA-OPF only cross-linked with the addition of PEGDA
linkers and thermal crosslinking initiators. Following crosslinking, TEA-OPF’s modulus was
20.67 – 1.77 KPa while the N2-OPF hydrogels was 82.59 – 10.62 KPa, roughly a three-fold
increase in compressive modulus. The presence of PEGDA also has the same trend of
increasing stiffness. Photoinitiated and thermal initiated crosslinking methods with PEGDA
caused photoinitiated hydrogels to have a higher modulus (189.23 – 56.04 KPa) than
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thermally initiated hydrogels (82.59 – 10.62 KPa). Statistics indicated that all OPF hydrogel
moduli were significantly different (p < 0.05).
Cell viability in the presence of polymer products
The influence of OPF oligomer products on cell growth and viability was examined
by 24 h incubation of NIH/3T3 cells with different OPF hydrogel solutions. The cytotoxicity
of all thermal initiator containing solutions was significant and resulted in low viability in
culture. With the addition of PEGDA, little increase in viability was observed. Furthermore,
PEGDA alone was shown to be acutely toxic to cells (Figure 3-8). To assess the cytotoxicity
of individual OPF products, solutions containing 25 wt% N2- and TEA-OPF in complete
growth media were exposed to cells for 24 h. As a result of residual TEA-HCl salts, cells
exposed to TEA-OPF alone were nonviable after 24 h, while cells exposed to N2-OPF were
over 90% viable in culture (Figure 3-8).
Discussion
The reaction of PEG and FuCl form linear polyester dimers, trimers, and eventually
oligomers in a step-growth process. The primary limitation of this reaction is the production
of HCl byproducts which must be isolated to prevent secondary reactions. Previously,
removal of HCl was accomplished by acid scavengers such as TEA, potassium carbonate, or
sodium hydroxide.16,23–28 In the current work, OPF synthesis using TEA was compared to an
OPF synthesis using nitrogen sparging. The use of sparging for the in situ removal of HCl
eliminates the need for an acid scavenger, thereby avoiding the production of difficult to
remove TEA salts.
For both reaction methods, formation of PEG/fumarate oligomers was confirmed by
1

H NMR. With greater olefin (6.87 ppm) to PEG (3.38–3.85 ppm) ratio and a reduction in
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signal from PEG hydroxyl end-groups (3.01 ppm), N2-OPF resulted in a greater degree of
oligomerization and larger molecular weight than TEA-OPF synthesis methods.1 Size
exclusion chromatography confirms a significant increase in N2-OPF molecular weight and a
more uniform product over TEA-OPF (Table 3-1 and Figures 3-4A and 3-5A, B).
In side-by-side comparison of TEA-OPF and N2-OPF reactions, temporal analysis of
the product demonstrates a limited maximum achievable molecular weight using TEA-OPF
methods. After 4 h, the maximum molecular weight was obtained by TEA-OPF with no
additional oligomerization at subsequent time points. In contrast, the oligomerization of the
N2-OPF method continues through 12 h (Figure 3-5). In step-growth processes, the final
conversion, and hence the average molecular weight, is affected by the concentration of
condensation byproducts.37 In situ removal of acid byproducts during nitrogen sparging
eliminates TEA salt formation allowing for the synthesis of a higher molecular weight OPF
(Figure 3-5A).1,22
In contrast to the nitrogen sparge method, TEA-OPF synthesis requires the additional
steps of filtration, recrystallization, and solvent washing to remove acidic by-products.1,2 The
incomplete removal of TEA salts during filtration, recrystallization, and solvent washing is
apparent in 1H NMR (1.4 ppm). The TEA-OPF also retains a brown coloration even after
repeated filtrations steps. Alternatively, the pure N2-OPF appears white immediately after
synthesis and does not require additional purification steps. Fluorescent analysis of eluted
product through GPC reveals the presence of a fluorescent molecule within TEA-OPF that is
absent in N2-OPF (Figure 3-4B). The fluorescent signal corresponds with the elution time of
TEA-OPF oligomers, indicating that the TEA salts are complexed to the OPF backbone. Cai
and Wang have previously reported the formation of cell-cytotoxic TEA complexes during
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polymerization of FuCl, in the presence of TEA, that cannot be completely removed during
purification.22 This behavior is confirmed in the cytotoxicity analysis of OPF products.
To examine the crosslinking capabilities of N2-OPF and TEA-OPF, two different
commonly used free-radical initiator systems were applied; AA/APS, a thermally activated
initiator, and Irgacure 2959, a UV activated initiator.1,2,20,21,38 In addition, hydrogels were
fabricated with and without PEGDA, a copolymer commonly used in the crosslinking of
PEG-based hydrogels due to the presence of highly reactive acrylic end groups. The use of
PEGDA allows for more efficient network formation of resulting hydrogels.39,40
Hydrogels were successfully crosslinked with AA/APS and PEGDA for both TEAOPF and N2-OPF. However, UV-initiated TEA-OPF/PEGDA and TEA-OPF hydrogels did
not crosslink adequately to maintain their three-dimensional structure when placed in water,
and subsequently fell apart. In comparison, N2-OPF readily crosslinked using both initiator
systems with and without PEGDA, highlighting the versatility of N2-OPF product (Figures
3-6 and 3-7). The inefficient removal of TEA salts in the TEA-OPF synthesis method is
likely a significant factor in the crosslinking behavior of TEA-OPF. The presence of TEA
salts limits UV intensity and penetration into the gels. Also, the TEA salts may directly
interfere with free-radical propagation and crosslinking reaction. To overcome the limitations
of TEA-OPF, previous groups have increased reaction time to an hour to fully crosslink
TEA-OPF.1,18,21 As OPF is commonly used as a biomaterial for cell encapsulation,
minimizing UV exposure time reduces cellular cytotoxicity.20,21 Crosslinking of hydrogels
was therefore limited to a 15 min exposure period, a time which has been shown to optimally
balance the crosslinking reaction with cell viability.21 Fully crosslinked OPF hydrogels
exhibited swelling characteristics dependent on the synthesis method and the use of the
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crosslinking molecule. Using AA/APS and PEGDA as the crosslinker, there was no
difference in swelling between TEA-OPF and N2-OPF hydrogels. While TEA-OPF did not
crosslink using the UV initiator, the choice of initiator did not influence the swelling of the
N2-OPF/PEGDA hydrogels. Furthermore, N2-OPF was able to form hydrogels without the
addition PEGDA, but resulted in a hydrogel with less crosslinking density and greater water
uptake capability (Figure 3-6A).17,41
All formulations were fabricated into gels of a 2:1 height to diameter ratio (diameter
= 5 mm). As seen with the swell ratio study, the only TEA-OPF formulation that maintained
its integrity was the TEA-OPF with PEGDA and the thermal initiator, so it was the only
TEA-OPF formulation studied. When compared to thermally crosslinked TEA-OPF with
PEGDA, N2-OPF was found to be four times stronger than the TEA-OPF hydrogels (Fig. 37). This is due to the lack of crosslinking efficiency of the TEA-OPF, in part, to the reduced
quantity of fumaryl groups in each TEA-OPF molecule. In addition, the presence of HCl salts
in the TEA-OPF could be hindering the crosslinking efficiency, which explains the reduced
amount of crosslinking, thus leading to a weaker modulus when compared to thermally
crosslinked N2-OPF with PEGDA.
The presence of PEGDA, a known linker for creating uniform polymer networks,
increased the moduli of both thermal and photoinitiated N2-OPF hydrogels.42,43 As such,
PEGDA allows for tunable compressive moduli ranging from 7 to 190 KPa. Interestingly,
when N2-OPF was cross-linked with PEGDA the modulus of UV crosslinking was increased
over thermal crosslinking methods. However, in the absence of PEGDA thermal initiation
method exhibited increased the modulus over UV methods. It is believed that the UV
crosslinking is more efficient at radicalizing the acrylates in PEGDA, resulting in a higher
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density of crosslinkable bonds, thus a stiffer material.42–44 The sol fraction of the N2-OPF
with PEGDA supports that more of the hydrogel solutions has been crosslinked (Figure 36).44
Since N2-OPF is the only product that can be crosslinked with and without PEGDA
and utilize both light and heat activated free-radical initiators, N2-OPF can be fabricated into
hydrogels with a wider range of mechanical properties, increasing its utility beyond that of
TEA-OPF.45
The importance of producing a polymer, which can be crosslinked without the
addition of PEGDA, becomes even more apparent when cell cytotoxicity is analyzed. With
the addition of PEGDA, significant cytotoxicity of NIH/3T3 cells was observed (Figure 3-8).
Similar behavior has been observed in low molecular weight PEG methyl ether acrylate (Mn
~ 480) solutions, caused by a decline in the antioxidant levels of glutathione and increased
intracellular reactive oxygen cytotoxicity.46 Furthermore, the exposure of cells to
uncrosslinked N2-OPF showed little cytotoxicity, while TEA-OPF solutions showed
significant cell death due to the persistence of cytotoxic HCl salts.22
Conclusion
Through nitrogen sparging, we have shown that OPF can be produced with decreased
postprocessing, increased product purity, greater oligomerization, and cell viability. These
properties lead to greater tunability in mechanical properties and a more versatile hydrogel
for biomedical applications. Instead of using TEA, an acid scavenger, in situ nitrogen gas
sparging eliminates the need for post-processing washes using ethyl acetate and ethyl ether,
which have proven to be inefficient while also being acutely toxic and potentially explosive
through peroxide formation. With greater oligomerization, N2-OPF has more unsaturated
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double bonds per molecule that can be used for crosslinking and addition of covalently bound
side chains. This straightforward method of fabrication allows for facile production that
eliminates postprocessing. The simplification of synthesis and elimination of impurities will
expand the utility of N2-OPF as a degradable hydrogel for cell culture, tissue engineering,
regenerative medicine, and therapeutic delivery, among other applications.
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Figures

Figure 3-1. Glassware set-up for the one-pot polycondensation of FuCl with PEG in
DCM using (A) the acid scavenger TEA or (B) nitrogen sparging to remove HCl
byproducts. (C) OPF reaction schemes for TEA-OPF and (D) (N2-OPF). (E)
Crosslinking structure of OPF oligomers through consumption of unsaturated double
bonds. DCM, dichloromethane; FuCl, fumaryl chloride; HCl, hydrochloric acid; N2OPF, nitrogen-sparged OPF; OPF, oligo(poly(ethylene glycol) fumarate); PEG,
polyethylene glycol; TEA, triethylamine.
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Figure 3-2. Samples of (A) precursor poly(ethylene glycol) (PEG, 4,600 g/mole)
polymer and OPF product using (B) triethylamine synthesis (TEA-OPF) and (C)
nitrogen sparge synthesis (N2-OPF).
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Figure 3-3. 1H NMR spectra of 4.6 K OPF from (A) nitrogen sparging or (B) TEA
scavenging methods. The presence of ester groups (b, 4.33 ppm) and olefin groups (c,
6.87 ppm) indicate bond formation and oligomerization of OPF. NMR (300 MHz)
measurements were carried out in CDCl3 (7.24 ppm). Some residual DCM can be
observed at 5.26 ppm with TEA contaminates at 1.43 ppm. CDCl3, deuterated
chloroform; 1H NMR, hydrogen nuclear magnetic resonance.
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Figure 3-4. (A) Representative elution profiles of OPF polymer products and pure 4.6 K
PEG as determined by GPC. Decreased retention time indicates higher molecular weight
N2-OPF oligomers. (B) Fluorescence profiles of OPF products and 4.6 K PEG were
collected in series with GPC. A large fluorescence peak was detected only in TEA-OPF
indicating unremoved TEA-HCl, Ex 250 nm/Em 410 nm. GPC, gel permeation
chromatography.
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Figure 3-5. During synthesis, small samples of (A) N2-OPF and (B) TEA-OPF product
were removed periodically over 14 h and analyzed by GPC. Each labeled peak (i–iv)
corresponds to an increasing oligomer length. TEA method limits molecular weight after
addition of fumarate to reaction vessel (4 h). Color images are available online.
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Figure 3-6. Swelling ratio of crosslinked OPF hydrogels using (A) thermal and (C) UV
initiator methods. Sol Fraction of crosslinked OPF hydrogels using (B) thermal and (D)
UV initiator methods. Swelling of N2-OPF without PEGDA was significantly greater
than all other gels, p < 0.05, n = 6. UV- initiated N2-OPF with PEG- DA had
significantly lower sol fraction than N2-OPF without PEGDA, p < 0.05, n = 6. D
indicates that gels did not crosslink sufficiently to be characterized. PEGDA,
polyethylene glycol diacrylate; UV, ultraviolet.
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Figure 3-7. Compression strength of OPF hydrogels with and without PEGDA linkers,
and UV or thermally crosslinked. N2-OPF hydro- gels crosslinked with both UV and
thermal initiators, with and without PEGDA linkers. TEA-OPF only crosslinked with
thermal initiation with PEGDA linkers. All hydrogel types had significantly different
moduli, p < 0.05, n = 8. N2-OPF with PEGDA hydrogels had a significantly stronger
modulus, p < 0.05, n = 8.
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Figure 3-8. Cell viability and cytotoxicity staining of NIH/3T3 (A) living controls
compared to cells exposed to (B) N2-OPF, (C) PEGDA, and (D) TEA-OPF solutions.
TEA-OPF as well as the required secondary crosslinker PEGDA shows acute toxicity,
while N2-OPF shows no toxicity over the live cell controls. Images are colocalized
(green = live, red = dead, Scale 50 mm). Color images are available online.
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Tables
Table 3 - 1. Material Properties of Triethylamine-Oligo(Poly(ethylene
glycol) Fumarate) and Nitrogen-Sparged Oligo(Poly(ethylene glycol)
Fumarate
Synthesis
Method

Percentage
of Yield

Tm (°C)

Percentage of
Crystallinity
(X)

M n (g/mol)

M w (g/mol)

PDI

Xn

TEA-OPF

86.8±9.2

60.7±0.4

64.1±2.1

7779±847

10,891±1368

1.4±0.04

1.8±0.2

N2-OPF

95.1±3.0

60.3±1.3

58.3±3.4

13,097±3494

17,271±3632*

1.3±0.06*

3.93±0.8*

All OPF synthesized with 4.6 K PEG.
M n, number average molecular weight; M w, weight average molecular weight; N 2-OPF, nitrogensparged OPF; OPF, oligo(poly(ethylene glycol) fumarate); PDI, polydispersity index; PEG,
polyethylene glycol; TEA, triethylamine; Xn, degree of polymerization.
*p < 0.05, n = 3–4.
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Supplemental
This section describes work of CTD that contributed to the published manuscript presented
above.
Cytotoxicity of nitrogen sparged OPF (N2-OPF) and triethylamine OPF (TEA-OPF)
Preliminary cell work run by C.T.D. to study the cytotoxicity of the N2-OPF to TEAOPF at varying weight percent concentrations to answer if the concentration of each OPF
polymer affects the viability of 3T3 cells and determine if N2-OPF is less cytotoxic than
TEA-OPF.
Materials and Methods
Reagents and Chemicals
Culture reagents Dulbecco’s minimum essential growth medium (DMEM), fetal
bovine serum (FBS), Dulbecco’s phosphate-buffered saline (PBS), penicillin–streptomycin
(Pen-Strep), fungizone (Fungi), trypsin-ethylenediaminetetraacetic acid 0.25% (TrypsinEDTA), and live/dead cell viability kit (Molecular Probes) were purchased from
ThermoFisher Scientific.
Condition Media Preparation
The conditioned media were prepared by dissolving various concentrations of N2OPF and TEA-OPF in primary media. The concentration of the OPFs in media ranged from
0.25%, 2.5%, 10%, and 25% (w/v) (Table S3-1). Briefly, a 25% (w/v) solution was made by
adding 500 mg of either N2-OPF or TEA-OPF into 1.5 mL of DMEM media. The 25% (w/v)
solution was then diluted down to the corresponding dilutions (10%, 2.5%, 0.25%) through
the addition of more media. The prepared solutions were filtered using a cellulose acetate
membrane filter (0.2 m pore diameter) for sterilization prior to administering to cells.
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Cytotoxicity of N2-OPF and TEA-OPF
NIH/3T3 cells were purchased from ATCC (CRL-1658) and cultured on a T-75
culture flask in DMEM medium supplemented with 10% FBS, 1% Pen-Strep, and 1%
fungizone and maintained at 37°C with 5% carbon dioxide. The culture medium was changed
every two days. At 80% confluences cells were enzymatically lifted by exposure to a trypsinEDTA solution (2 mL/flask). Cells were seeded onto 48-well tissue culture plates in media at
32,000 cells/well and allowed to attach for 24-hours at culture conditions (37°C, 95% RH,
5% CO2). After 24-hours the media was aspirated and three wells of attached 3T3s were
exposed to 200 μL of the prepared conditioned media treatment and incubated for 2-hours
and 24-hours. Treatment solutions were aspirated, and cells were washed with 200 μL of
DPBS to remove any remaining conditioned media. For a positive (live) control and negative
(dead) control, 3T3s were cultured in media and treated with 70% (v/v) ethanol solution for
30-minutes. LIVE/DEAD reagent [combination of 4 M ethidium homodimer-1 (EthD-1) and
2 M calcein AM] was prepared following the protocol provided by the manufacturer and 100
μL of the LIVE/DEAD reagent was added to each sample well and incubated in the dark for
30-minutes at room temperature. Cells were then viewed on an inverted microscope with a
fluorescence attachment and microscope filter cubes for calcein AM (Live, Green, 494/517
nm) and EthD-1 (Dead, Red, 528/617 nm).
Fluorescent image processing was performed with Fiji (NIH/ImageJ). Briefly, an
image was split into its corresponding red, green, and blue channels. The blue channel was
removed because there was no blue fluorescent stain used and the red and green channels
were then merged into one image. Finally, to reduce the background noise and focus on the
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intensity of the fluorescent data, the brightness and/or contrast was adjusted to incorporate
only signals associated with the live or dead stain of a cell.
Results
Initially, 3T3 fibroblasts were exposed to N2-OPF or TEA-OPF conditioned media for
24-hours. The lower concentrations of 0.25% and 2.5% (w/v) for both polymer solutions
resulted in adhered cells, spindled morphology, and high viability (Figure S3-1). Low
amounts of cytotoxicity were observed for the 10% (w/v) condition media for both polymers.
Complete cell death was observed for 25% (w/v) N2-OPF and TEA-OPF condition media.
Biocompatibility differences between the two polymers were not found and both polymer
solutions followed the same trend of increased cytotoxicity as polymer concentration
increased.
Further investigation into the 10% and 25% (w/v) concentrations were run by
exposing 3T3 cells to N2-OPF and TEA-OPF conditioned media for 2-hours, then analyzed
for cell viability. Like the 24-hour test, both N2-OPF and TEA-OPF at a concentration of
25% (w/v) had cytotoxic effects on 3T3 fibroblast (Figure S3-2). The 10% (w/v)
concentration had varying results. Cells exposed to the N2-OPF solution showed higher
cytotoxicity, compared to the TEA-OPF treatment.
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Table S3-1. N2-OPF and TEA-OPF treatments at varying concentrations and the
formulations to make each conditioned media treatment.
Treatments
(w/v)

Formulation and Dilution of Treatments

Solution
Volume

25% N2-OPF

500 mg N2-OPF into 1.5 mL DMEM media

N2-OPF Stock

10% N2-OPF

400 μL of N2 Stock into 600 μL DMEM media

1 mL

2.5% N2-OPF

100 µL of N2 Stock into 900 µL DMEM media

1 mL

0.25% N2-OPF

10 µL of N2 Stock into 990 µL DMEM media

1 mL

25% TEA-OPF

500 mg TEA-OPF into 1.5 mL DMEM media

TEA-OPF Stock

10% TEA-OPF

400 μL of TEA-OPF into 600 μL DMEM media

1 mL

2.5% TEA-OPF

100 µL of TEA-OPF into 900 µL DMEM media

1 mL

0.25% TEA-OPF

10 µL of TEA-OPF into 990 µL DMEM media

1 mL
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Figure S3-1. Cytotoxicity analysis of 3T3 fibroblasts exposed to N2-OPF (A-D) or TEA-OPF
(E-H) conditioned media for 24-hours with solution concentrations of 0.25% (A, E), 2.5%
(B, F), 10% (C, G), 25% (D, H). Live (I) and dead (J) controls. Live = Green, Dead = Red,
Scale = 100 μm
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Figure S3-2. 3T3 fibroblasts exposed to N2-OPF (A, B) or TEA-OPF (C, D)
conditioned media for 2-hours. Concentrations of 10% (A, E) and 25% (B, D)
were tested for further cytotoxic effects. Live (E) and dead (F) controls.
Live = Green, Dead = Red, Scale = 100 μm
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Abstract
Cardiovascular disease is the number one cause of death in the United States. Calcific
aortic valvular disease (CAVD) is the leading contributor to cardiovascular disease and is
characterized by thickening and stiffening of the aortic valve leaflets through fibrotic and
calcific nodule build-up. The resident cell population found in the heart valve leaflets are
valvular interstitial cells (VIC). Healthy aortic valve leaflets are maintained by quiescent
(qVIC) and activated VIC (aVIC) phenotypes but, through environmental factors that are not
well understood, VICs can differentiate into calcific nodule forming osteoblastic-like VICs
(obVIC). Recently, it was found the positively charged surfaces cause VICs to differentiate
into obVICs and produce calcific nodules. Therefore, this work aims to investigate the effects
of charged three-dimensional (3D) environments on VIC phenotype. It is hypothesized that
positively charged environments will stimulate VICs to become obVICs. To design a 3D cell
culture platform oligo(poly(ethylene glycol) fumarate) (OPF), a biodegradable polymer
containing unsaturated double bonds, and a cell attachment biomolecule were synthesized
and combined with poly(ethylene glycol) diacrylate (PEGDA) cross-linker to form
hydrogels. The positively charged monomer [2-(Methacryloyloxy)ethyl] trimethylammonium
chloride (MAETAC) was then incorporated into the hydrogel network for testing
environmental charge effects on VICs. It was found that concentrations up to 200 mM of
MAETAC could be incorporated into the OPF and PEGDA hydrogel network. It was also
found that VIC populations were not supported by the OPF and PEGDA hydrogels due to the
pH of the OPF and PEGDA molecular weight (Mn 575). Finally, a more water-soluble photoinitiator was investigated for cross-linking speed and found to decrease cross-linking time
which decreased the amount of UV (365 nm) light VICs were exposed to during the
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encapsulation process. It was concluded that although the current OPF and PEGDA hydrogel
platform did not support VIC growth, further investigation into neutralizing the OPF’s and
increasing the PEGDA molecular weight may improve VIC survival through encapsulation
and in culture.

83

1. Introduction
With 859,125 annual deaths, cardiovascular disease is the number one cause of death
in the United States. Globally it accounts for 17.8 million annual deaths.1,2 Calcific aortic
valvular disease (CAVD) is a leading cause of cardiovascular disease. This disease is
characterized by increased thickness and reduced flexibility of the aortic valve.1–3 The
rigidity of the valve restricts the normal motion of the valve and disrupts the coaptation of the
valve leaflets, causing stenosis (Figure 4-1). Stenosis leads to regurgitation of oxygenated
blood back into the heart ventricle subsequently lowering blood pressure resulting in poor
circulation to the body and heart.4 Significantly, poor circulation to the coronary arteries
results in a negative feedback loop where insufficient amounts of oxygenated blood is
delivered to the heart. These conditions force the heart to work harder to pump more blood to
the body producing more stress on the aortic valve, further exacerbating CAVD and
ultimately leading to heart failure if left untreated.
Healthy leaflets are maintained by a heterogeneous cell population called valvular
interstitial cells (VIC). The most common phenotypes found throughout the leaflet are
quiescent (qVIC) which are characterized by a cobbled morphology in vitro (Figure 4-2).
During normal valve activity qVICs maintain valvular structure and stability through low
extracellular matrix (ECM) turnover. In response to inflammatory factors and cytokines,
qVICs differentiate into a highly proliferative, activated VIC (aVIC) phenotype to help repair
the damaged leaflet. Activated VICs are characterized by an elongated-spindle morphology
and expression of ⍺-smooth muscle actin (Figure 4-2). Normally, after the damage has been
repaired and inflammation has reduced, aVICs undergo apoptosis or revert to qVICs. If
aVICs remain, extensive remodeling and disorganization of the heart valve leaflet occurs and
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leads to fibrosis.3 Over time, the fibrotic ECM stiffens the valve leaflet contributing to the
differentiation of aVICs into an osteoblastic-like (obVIC) phenotype. Osteoblastic-like VICs
are characterized by an irregular morphology and expression of osteoblastic markers such as
osteocalcin and transforming growth factor β-1. Most notably, obVICs produce calcific
nodules in the ECM of the leaflet which, in conjunction with the buildup of fibrotic tissue,
promotes nearby VICs to switch to obVICs further propagating the disease throughout the
valve (Figure 4-2).
Despite its prevalence, the factors that cause VICs to become osteoblastic-like remain
unclear. Environmental factors such as material properties, biological cues, and soluble
factors all have been shown to alter VIC phenotype. Specifically, material properties such as
substrate stiffness and chemistry have been used to direct VIC phenotype.5–8 When VICs are
grown on tissue culture polystyrene (TCPS), a gold standard for tissue culture, the stiff
plastic (30.6 ± 10.9 GPa) support aVICs. The aVICs proliferate quickly until they become
fully confluent at which time they differentiate into obVICs and start producing calcific
nodules. In comparison, the valve has been reported to have a modulus of 25 kPa,
considerably less stiff than the TCPS. Evidence based on substrate stiffness and CAVD valve
stiffening suggest that mechanical factors may induce VICs to become specific phenotypes.7
Furthermore, substrate chemistry is consistently used to improve cell attachment and control
cell phenotype.9–19 Tissue culture polystyrene undergoes plasma treatment which oxygenates
the ring of polystyrene. This imparts a negative charge and increases cell attachment and
viability. Additionally, we previously studied how charged surfaces affect VIC phenotype by
seeding VICs on top of charged self-assembled monolayers made from alkanethiols. These
monolayers either presented a positive (NH3+) or a negative (COO-) charge to one side of
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seeded VICs. It was found that over 7-days VICs exhibited surface-dependent differences in
morphology and osteoblastic potential. Positively charged surfaces had the most obVICs and
calcific nodule formation. The negatively charged surfaces showed majority aVICs and no
calcification.20 Based on these findings, material properties are of interest to design microenvironments for studying CAVD development, drug development, and improving current
treatments.
Due to the lack of physiologically relevant laboratory models and recent advances in
valvular tissue engineering there has been an aim to create three-dimensional (3D) microenvironments that represent the valve milieu. Within the tissue engineering field, polymer
networks such as hydrogels that are highly hydroscopic have been used extensively to create
soft tissue. One such polymer, poly(ethylene glycol) (PEG), is a popular synthetic polymer
that is extensively used. Poly(ethylene glycol)’s biocompatibility, hydrophilicity, and bioinert
properties have made it useful for creating and systematically controlling microenvironments for tissue engineering applications.21–23 Specifically, PEG dendrimers have
been combined with biodegradable and cell attachment peptides to improve and study
degradation rate on VICs in 3D cell culture.24–30 Moreover, linear PEG has been
functionalized with [2-(methacryloyloxy)ethyl]trimethylammonium chloride (MAETAC) to
create positively charged substrates for growing cells.15–19,31
In addition to PEG’s individual utility, PEG has been used to create co-polymers with
a variety of properties for 3D cell culture. One such co-polymer made from PEG is
oligo(poly(ethylene glycol) fumarate) (OPF) a biodegradable, linear polyester that contains
multiple unsaturated fumarate bonds in its backbone that are useful for functionalization with
moieties and cross-linking the polymers into a hydrogel (Figure 4-3). Since OPF is a PEG
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based polymer, cell attachment is poor. To mediate this problem, tethered RGD cell
attachment groups have been cross-linked into OPF hydrogels to support cell growth.32–34
Also, chemically charged end groups, like MAETAC, have been used to make charged OPF
hydrogels for cell studies.9,10,12,35 This makes OPF ideal for systematically creating microenvironments to investigate how material properties, like substrate chemistry, affect VICs
behavior.
Currently, there is little research on VICs behavior to charged substrates. Through our
previous work with charged self-assembled monolayers we found that positively charged
surfaces direct VICs to differentiate into obVICs and form calcific nodules. We hypothesize
the same phenomenon will occur when VICs are scaled up and grown in a positively charged
3D culture platform. The objective of this work is to fabricate a positively charged OPFbased hydrogel, with tunable charge densities for testing VICs response to positively charged
3D micro-environments. To build the hydrogel platform, OPF and PEGDA cross-linker were
used to form the base hydrogel network. Cell attachment peptide RGD and positively
charged MAETAC were photo cross-linked into the hydrogels during VIC encapsulation.
Then VIC cytotoxicity to the charged hydrogels components, in 2D culture studies, and
within the OPF/PEG hydrogels were tested. Finally, a quicker photo-initiator was tested to
improve cross-linking speed of the OPF/PEG hydrogel for the encapsulation of VICs
process.
2. Materials and Methods
2.1 Synthesis of Oligo(Poly(Ethylene Glycol) Fumarate)
Oligo(poly(ethylene glycol) fumarate) was synthesized as outlined in Rush et al.36
Briefly, prior to running of the reaction, fumaryl chloride (FuCl, TCI, F0152) was distilled
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and poly(ethylene glycol) (PEG 1,000 Da, Sigma-Aldrich, 807488) was azeotropically dried
with toluene (Sigma-Aldrich, 244511 ). Fifty grams of PEG (1,000 Da) was dissolved in
dichloromethane (DCM, VWR, BDH1113) in a 3-neck round bottom flask. The reaction was
maintained under a nitrogen blanket to impede oxygen inhibition of the polymerization. The
PEG solution was stirred vigorously while FuCl (0.9:1 molar ratio FuCl:PEG) was added
dropwise over 4-6 hours to the reaction. Throughout the reaction, removal of hydrochloric
acid (HCl) byproduct was accomplished by nitrogen (N2) gas sparging using a fine fritted gas
dispersion tube (Chemglass, CG-203-01) at a flow rate of 2.0 SCFH. The removed HCl was
neutralized in a 1 M NaOH (VWR, 221465) in ethanol (Koptec, V1001). The reaction was
allowed to progress for 48-hours under continual sparging with periodic DCM refills. At the
completion of the reaction, the solvent was removed via rotary evaporation (Buchi, R-215).
2.2 Synthesis of Acrylate-Poly(Ethylene Glycol)-CGRGDS Biomolecule
To create the acrylate-poly(ethylene glycol)-CGRGDS (PEG-RGD) biomolecule,
acrylate-poly(ethylene glycol)-succinimide (Mn 3400, Laysan, SVA-3400) and CGRGDS
(Sigma-Aldrich) were dissolved together in a 50 mM sodium bicarbonate buffer solution
(pH 8.5). The reaction progressed for 2 hours at room temperature under a nitrogen
environment at room temperature with vigorous stirring. Upon completion of the reaction,
the solution was transferred into dialysis tubing (Spectrum Labs, 132108) with a pore size of
2,000 Da and dialyzed in ultra-pure water with periodic bath changes for 24-hours. The final
PEG-RGD was freeze dried and stored under nitrogen at -20oC.
2.3

Proton-Nuclear Magnetic Resonance Spectroscopy
Proton nuclear magnetic resonance (1H-NMR) spectroscopy was used to assess

chemical structure of the OPF and the PEG-RGD biomolecule with an Avance III Solution
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300 (300 MHz, Bruker, Massachusetts). Samples were prepared by dissolving 50 mg of
OPF into 1 mL of deuterated chloroform (Millipore Sigma, Germany) while 50 mg of PEGRGD was dissolved in 1mL of deuterium oxide (Cambridge Isotope Lab, 7789-20-0).
Samples were loaded into borosilicate NMR tubes (5 mm diameter, Wilmad, New Jersey)
and scanned 16 times. Spectra were first processed by calibrating the baseline through the
solvent peaks, deuterated chloroform at 7.26 ppm and deuterium oxide at 4.8 ppm, then
sample peaks were identified and used to determine chemical structure.
2.4

Gel-Permeation Chromatography
The molecular weight and polydispersity index of OPF was measured using a Waters

HPLC with a PLgel Mixed-C column (5 μm, Agilent Technologies, PL1110-6500) equipped
with a refractive index detector (Waters, 1515, Waters 2414). The solvent used in the HPLC
system was chloroform supplemented with 0.5% triethylamine. OPF was prepared in
chloroform at a concentration of 5 mg/mL of solvent and filtered through a 13 mm syringe
filter (VWR 28145-493), prior to the sample solution being loaded into a 1.5 mL vial
containing a rubber injection lid. Two standards were created using a range of known
poly(ethylene glycol) (Agilent Technology, PL2070-0100) weights. Standard A contained
the following molecular weights (106, 410, 1,020, 3,870, 18,100 g/mole) and standard B
contained the following molecular weights (194, 615, 1,450, 8,160, 21,160 g/mole). A
calibration curve was created based on both standards and used to compare the OPF samples.
The standards and samples were run at a flow rate of 1.0 mL/minute with a triplicate sample
size.
2.5

Fabrication of Oligo(Poly(Ethylene Glycol) Fumarate) Hydrogels

The base OPF and poly(ethylene glycol) diacrylate (PEGDA, Mn 575) hydrogel was
made with the following recipe as outlined in (Table 4-1). Briefly, OPF and PEGDA were
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mixed in a final PBS solution at a 5:1 weight ratio (OPF: 20.83 wt%, PEGDA: 4.17 wt%).
[2-(Methacryloyloxy)ethyl]trimethylammonium chloride (MAETAC, Sigma-Aldrich,
408107) was added to the OPF/PEG hydrogels at 50 mM, 100 mM, 200 mM, 400 mM
concentrations to create the positively charged hydrogels for the sol-swell analysis. PEGRGD biomolecule was added to the OPF/PEG solutions at concentrations of 1 mM and 2
mM for VIC encapsulation studies. Positively charged hydrogels used for the sol-swell and
the PEG/PEGDA hydrogels used for encapsulation tests were cross-linked with the photoinitiator Irgacure 2959 (0.05 wt%, Sigma-Aldrich, 410896) in a UV Crosslinker box
(Analytik Jena, CL-1000) for 15 minutes (365 nm, 10 mJ/cm2).
2.6

Sol Fraction & Swelling Ratio of Charged Hydrogels & LAP Cross-Linked Hydrogels

Two photo initiators, I2959 and LAP, were tested to determine the efficiency of
crosslinking charged hydrogels. After cross-linking the hydrogels, they were weighed to
obtain the weight initial (Wi) and placed into 10 mL of phosphate buffer saline (PBS)
overnight. Swollen hydrogels were then weighed to obtain a swollen weight (Ws). Finally,
hydrogels were dried in a vacuum chamber for 48-hours and reweighed to obtain the weight
dried (Wd).
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝐷𝑒𝑔𝑟𝑒𝑒 =
𝑆𝑜𝑙 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =

!! # !"
!!

!# # !"
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The following method was used for analyzing both the charged hydrogels and LAP crosslinked hydrogels.
2.7

Cytotoxicity of Encapsulated Valvular Interstitial Cells

VICs were obtained from porcine aortic valves (Hormel) through a collagenase digest
procedure and stored in liquid nitrogen.37 VICs were passaged in a tissue culture polystyrene
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(TSPS) flask with Media 199 (Hyclone, SH30253.01) containing 10% fetal bovine serum
(ThermoFisher, 10438034), 1% penicillin/streptomycin (ThermoFisher, 15140122), and 1%
amphotericin B (ThermoFisher, 15290026) at 5% CO2, 37oC, and 90% humidity. After 2-3
passages, cells were frozen down and stored in liquid nitrogen. After thawing, cells were
passaged 2-3 times before use.
To prepare cells for encapsulation, VICs were removed from TCPS surfaces through
a trypsin/EDTA digest (ThermFisher, 25200072) and suspended in a OPF/PEG solution,
sterile filtered using 0.22 μm syringe filter, at a concentration of 10x106 cells/mL.24,38–42 The
cell-laden hydrogel solution was then pipetted into Teflon molds with wells 6 mm diameter x
1 mm height and UV crosslinked for 15 minutes (365 nm, 10 mJ/cm2). Hydrogels were then
removed from molds and placed into 48-well TCPS plate (Corning Inc, 3548) with 1mL of
Media 199. Subsequently, the well plate was placed on an orbital shaker table and agitated in
an incubator (37oC, 5%, CO2) for 24-hours.
Live/Dead fluorescent analysis (calcein AM, ethidium homodimer-1, Molecular
Probes-Invitrogen, C3100MP) was run to determine cell viability. Briefly, 1 mL of the
staining solution was administered to each hydrogel construct and allowed to incubate for 30minutes (room temperature, dark). A live control containing just cells seeded on the well
plate and a dead control of cell laden hydrogels exposed to 70% ethanol for 30 minutes was
used. Cells were then viewed on an inverted microscope with a fluorescence attachment
where red stained cells indicated cell death and green stained cells signified live cells.
Brightfield and florescent images were taken of the cell laden constructs and cells were
visually analyzed to determine if VICs survived the encapsulation process with OPF/PEG
and PEG-RGD biomolecules.
2.8

pH of Oligo(poly(ethylene glycol) fumarate)
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OPF was dissolved in PBS (pH 7.4) at a 20.83 wt% representative of the OPF
concentration used to form the hydrogels. The solution was mixed for 1-hour in the dark at
which the pH (VWR, SB70P) of the OPF solution was measured.
2.9

Cross-Linking Kinetics of LAP Photo-Initiator
In this study, effects of LAP concentration, UV intensity, and cross-linking time was

examined for faster crosslinking efficiency when compared to the currently used I2959 (15minutes UV exposure time at 0.05 wt%). LAP was tested at 0.03, 0.05, and 0.075 wt%
(Table 4-2). Additionally, UV intensities of 2, 5, and 10 mW/cm2 were used in a UV
Crosslinker box. The hydrogels were cast in syringe molds and cross-linked for 1.0, 1.5, or
3.0 minutes. The final hydrogels were analyzed through the sol fraction and swelling ratio
analysis as previously outlined above.
2.10 Cytotoxicity of Leachable Components & the Hydrogel Solution

To determine the cytotoxicity of the materials leached products from the OPF/PEG
hydrogel, the OPF/PEG hydrogel solution, and the individual polymer components were
exposed to cells. A condition media with the leached components from the OPF/PEG
hydrogels was prepared by soaking a hydrogel scaffold (1 mm by 6 mm, height to diameter)
in 1 mL of VIC media for 24-hours. The conditioned media, the OPF/PEG hydrogel solution,
a solution of OPF (20.83 wt%) in PBS, and a solution of PEGDA (4.17 wt%) in PBS were
sterile filtered prior to application to cells.
VICs were seeded in a 48-well plate at a seeding density of 95,000 cells/well. Along
with the conditioned media and OPF/PEG hydrogel solution, 100 μL of each individual
component solution, OPF and PEGDA, were administered to the VICs. After 20-minutes the
treatment solutions were removed and the VICs washed carefully with 200 μL of PBS.
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Finally, the Live/Dead stains were administered and the VICs were imaged under an inverted
microscope with a fluorescent source attached.
2.11 Statistics

A Shapiro-Wilks and Levene’s tests were used to determine the normality and equal
variance within and between groups. A Kruskal-Wallis H analysis was used to determine
statistical differences between multiple groups. The Kruskal-Wallis H Test is a rank-based
nonparametric analysis that measures the statistical differences between two or more
independent variables. If a statistical difference was found, Dunn’s multiple comparisons
post-hoc test with a Bonferroni correction at a 95% confidence interval (α<0.05) was used to
determine which group(s) were significantly different from each other. The Dunn’s test is a
nonparametric multiple comparisons test and the Bonferroni correction was used to reduce
error rates amongst multiple comparisons. All error bars are calculated based on mean ±
standard deviation and statistical analyses were performed using Microsoft Excel and
RStudio. Fluorescent images were analyzed using the Fiji software a version of NIH ImageJ
software.
3. Results
3.1 Oligo(Poly(Ethylene Glycol) Fumarate) and Poly(Ethylene Glycol)-RGD
Characterization
OPF was synthesized in three 50-gram batches and characterized through 1H-NMR
and GPC. The NMR spectrum showed characteristic olefin (6.8-7.0 ppm), PEG (3.4-4.0
ppm), and ester (4.3-4.5 ppm) peaks distinct to OPF. Confirming that the polymer has been
synthesized (Figure 4-4).19 The GPC analysis showed that OPF had a weight-average
molecular weight (Mw) of 8036 ± 115 g/mole and a number-average molecular weight (Mn)
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of 5,287 ± 516 g/mole with a PDI of 1.52 ± 0.133 (n=3). Calculations based on OPF’s Mw
indicated that on average there were 7 ± 0.1 double bonds per OPF molecule (Table 4-1).
Visual observations showed that OPF is a white powder that partially clumped together. The
visual characteristics of OPF are similar to that of the PEG 1000 g/mole precursor monomer.
Moreover, due to the PEG in the backbone, OPF readily dissolved into an aqueous solution.
During the formation of acrylate-PEG-RGD, the succinimide group on the end of the
PEG chain is being replaced by the CGRGDS peptide and removed through dialysis. NMR
comparison of the acrylate-PEG-succinimide (Mn 3400) molecule to the synthesized PEGRGD biomolecule showed that succinimide peaks (2.7-2.9 ppm) were present in the initial
acr-PEG-succinimide molecule and had disappeared in the final biomolecule spectrum
(Figure 4-5). Additionally, the PEG-RGD spectrum retained the acrylate (5.8-6.9 ppm) and
PEG (1.4-1.8, 2.5-2.7, 3.2-4.0, 4.1-4.4.3 ppm) peaks found in the original acrylate-PEGsuccinimide molecule. The spectrum also showed peptide peaks indicating that the CGRGDS
had been immobilized onto the polymer and not removed during dialysis (Figure 4-5).13,14
Visual inspection of the final PEG-RGD biomolecule showed a white powder that had small
grains and easily went into an aqueous solution.
3.2 Hydrogel Formation of Positively Charged Hydrogels
To measure how increasing MAETAC concentrations affected the formation of the
base OPF/PEG hydrogel (OPF 20.83 wt%, PEGDA 4.17 wt%, I2959 0.1 wt%) physical
properties, an analysis of the hydrogel’s swelling ratio and sol fraction was run with
MAETAC concentrations 0 mM, 50 mM, 100 mM, and 400 mM. Only the 400 mM group
had a swelling ratio that was significantly different from the 100 mM treatment (p-value =
0.0433) (Figure 4-6, TOP). Visual observations of the 400 mM MAETAC hydrogels
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revealed that they did not retain their casted shape when handle and were susceptible to
falling apart.
The sol fraction was used to determine how much of the OPF/PEG hydrogel solution
was not cross-linked into the polymer network. The 400 mM concentration was found to be
significantly different from the 50 mM and OPF/PEG control (p-values=0.00927, 7.04x10-5).
The control (OPF/PEG), 50 mM, and 100 mM concentrations had on average a sol fraction
between 50-60%, while the sol fraction was >60% for the 400 mM concentration (Figure 46, BOTTOM) which signifies that more gel solution is failing to cross-link into a polymer
network as the MAETAC concentration increased.
3.3 Cytotoxicity of Encapsulated Valvular Interstitial Cells
Viability tests to determine if VICs survived the encapsulation process were
performed with the control (OPF/PEG) hydrogels and compared to hydrogels containing
1mM or 2 mM PEG-RGD biomolecule. Initial observations show that VICs are dead in all
groups. It was also found that within the cross-linked hydrogels there were aggregates of
VICs leading to uneven distribution of cells throughout the hydrogel with all test groups
(Figure 4-7). Furthermore, VICs displayed a rounded morphology despite the presence of
cell attachment peptides. Therefore, it was concluded that something other than PEG-RGD
concentration was causing VICs to not survive encapsulation. Since the OPF/PEG hydrogels
with 1 mM and 2 mM PEG-RGD resulted in complete cell death, positively charged
hydrogels were not tested for VIC survival during encapsulation. Further experiments
explored what could be contributing to the hostile conditions leading to the VIC death.
3.4

pH of Oligo(poly(ethylene glycol) fumarate)
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During the OPF polycondensation reaction hydrochloric acid is generated as a
byproduct. Although a majority of the HCl is removed during the reaction, residual amounts
of HCl could remain in the OPF and be the cause of the high mortality of VICs during the
encapsulation. To investigate this hypothesis, OPF was added to PBS (pH 7.4) at the
concentration (20.83 wt%) used for encapsulating VICs. The pH of the PBS solution dropped
from 7.4 to 3.7, indicating that the OPF still contained considerable amounts of acidic
contamination. Therefore, to mediate the extreme acidity, OPF was added to a PBS solution
whose pH was adjusted to 11.5 with sodium hydroxide. The pH 11.5 was established to be
basic enough to buffer the acidity of the OPF, resulting in biocompatible pH of 7.4.
3.5

Cross-linking Time of LAP Photo-Initiator
UV exposure during photo cross-linking the hydrogels was investigated. LAP was

investigated as a photo-initiator that would decrease that amount of time VICs were exposed
to UV light. All the OPF/PEG hydrogels cross-linked with different concentrations of LAP
(0.03, 0.05, 0.075 wt%) and varying UV intensities (2, 5, 10 mW/cm2) for 3 time periods
(1.0, 1.5, 3.0 minutes) and had a swelling ratio roughly 7.0 (Figure 4-8). There were not any
statistical differences between the swelling ratio when comparing LAP concentration, UV
intensities, or time periods. The sol fraction of all the groups were between 0.4-0.5. Although
there was not any statistical difference found when comparing LAP concentration, UV
intensities, or time periods, there was a general trend that indicated that as the LAP
concentration increased the sol fraction decreased.
3.6 Cytotoxicity of Leachable Components & the Hydrogel Solution
The components that VICs encounter: leached products from the OPF/PEG hydrogel,
the hydrogel solution (OPF, PEGDA, LAP, PBS), and the individual components OPF and
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PEGDA of the hydrogel solution, were tested for their potential cytotoxicity. VICs were
exposed to treatments for 20-minutes, indicative of the time needed to process and
encapsulate the cells. The conditioned media was created by soaking a cross-linked
OPF/PEG hydrogel (1mm:6mm H:D) in 2mL of media for 24 hours. After the hydrogel had
been removed, the conditioned media was applied to the cells for 20 minutes. Images of
VICs treated with the conditioned media show that there was high cell survival and cells
appeared to stay attached to the TCPS well surface (Figure 4-9). Additionally, VICs
presented a spindle morphology similar to the live control, indicating that leached products in
the conditioned media had little effect on VIC viability and morphology.
Results from the hydrogel solution treatment indicated that there is cell death occurs
when VICs are exposed to the hydrogel solution used to suspend cells prior to encapsulation.
This is evident by the number of cells that are dead and the morphology of the VICs found in
the fluorescent images (Figure 4-9). Valvular interstitial cells presented a rounded
morphology, contradictive to the spindle shape found in the live control. Moreover, the VIC
cells’ membrane appeared to be forming and releasing vesicles.
Based on results from the hydrogel solution treatment, the components OPF and
PEGDA of the hydrogel solution were further investigated for their cytotoxicity. A solution
of OPF (20.83 wt%) was made in PBS, with a final pH 7.4. Results from the OPF solution
treatment showed high cell viability, with VICs adhered to the plate surface. Furthermore,
VICs presented a spindle morphology (Figure 4-9). The PEGDA (Mn 575) linker was
dissolved in regular PBS (pH 7.4) at a concentration of 4.17 wt%. VICs responded to the
PEGDA solution treatment like they did with the hydrogel solution. There was significant
amount of cell death and lift off the plate surface (Figure 4-9). Additionally, the cells’
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membrane also showed vesicle formation, consist with the hydrogel solution findings
(Figure 4-10).
Overall, the OPF solution and conditioned media showed high cell viability with
VICs being in an activated morphology. The hydrogel solution which the VICs come into
direct contact during processing and encapsulation is causing significant cellular stress.
Specifically, the PEGDA (Mn 575) was shown to be cytotoxic.
4. Discussion
Through visual observation, OPF had material properties (white powder) similar to its
PEG (Mn 1,000) precursor. Moreover, due to the polymer having a majority of PEG, OPF
readily dissolved into the PBS solution, which is advantageous for encapsulating cells.
The cell attachment biomolecule, PEG-RGD, was synthesized through the replacement of a
succinimide group in the off the shelf acrylate-PEG-succinimide molecule with CGRGDS
peptide sequence.34,45–47 Chemical analysis through 1H-NMR showed that the peptide was
attached to the acrylate-PEG molecule and succinimide was removed through the presence of
the acrylate and the PEG and the absence of the succinimide peaks (Figure 4-5). Although
peptide peaks were hard to delineate due to the overlap with PEG peaks, the NMR spectrum
was comparable to that of Peter and Tayalia.48 Upon visual inspection of the final PEG-RGD
biomolecule, it was found that the polymer was a white powder, consistent with the acrylatePEG-succinimide, rather than the airy and less dense consistency of the CGRGDS peptide.
Using the OPF/PEG hydrogel recipe (Table 4-1) a sol-swell analysis was run to
determine the largest concentration of MAETAC that could be incorporated into the polymer
network. It was expected that as the MAETAC concentration increased to the point that all
the excess OPF double bonds were used, MAETAC would start using OPF and PEGDA
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double bonds necessary for forming the polymer network leading to an increase in the
swelling ratio and, ultimately, loss of hydrogel integrity. A general trend from the sol-swell
analysis showed that as the MAETAC concentration increased so did the swelling ratio,
consistent with what was expected (Figure 4-6). Additionally, as MAETAC concentration
increased over 200 mM it was visually observed that hydrogels were very swollen and
susceptible to breaking apart easily. These results from the swelling ratio were comparable to
other groups who used OPF or PEGDA based hydrogels for cross-linking MAETAC at
concentrations ranging from 50 mM to 400 mM.9,10,17–19 Additionally, other groups using
OPF and MAETAC to make positively charged hydrogels had similar sol fractions as the
OPF/PEG with MAETAC are comparable.9,10,12 The sol fraction analysis supported the
swelling ratio results. The general trend showed that as MAETAC concentration increased
the sol fraction also increased (Figure 4-6) signifying that as the MAETAC concentration
increased more of the polymer molecules are failing to cross-link into the polymer network.
This supports the idea that as MAETAC increases it starts binding to necessary double bonds
for hydrogel formation.
As previously stated, VICs seeded on positively charged surfaces were shown to
become osteoblastic-like as indicated by the formation of calcium nodules.1 To test whether
this same phenomenon occurs in 3D, VICs were to be encapsulated in the positively charged
hydrogels with varying concentrations MAETAC and cultured over a period of 7-days.
Unfortunately, initial observations of VICs encapsulated in hydrogels made of just
OPF/PEG, without any MAETAC, displayed high VIC mortality (Figure 4-7, A). These
results were surprising because OPF synthesized with 1 KDa PEG has been shown to have
moderate biocompatibility when the OPF macromer was exposed to cells at varying
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concentrations (0.4% - 40% w/v) for 2-hours and 24-hours.22 In addition, PEGDA and OPF
has been used extensively for cell encapsulation applications.33,34,49 Therefore, further
encapsulation experiments investigated if increasing the concentration of the PEG-RGD
biomolecule would increase VIC viability within the control, OPF/PEG hydrogels.
Two concentrations of the cell attachment biomolecule PEG-RGD (1 mM and 2 mM)
was tested to determine if the cell death was due to VICs inability to adhere to the polymer
scaffold.27,50,51 Results show that both 1 mM and 2 mM concentrations did not support VIC
viability (Figure 4-7, C-F) despite that PEGDA based hydrogels mixed with these
concentrations have supported cells even VICs previously.23,34,43,45–47,52 It was concluded that
VICs were not dying from lack of adherence peptides within the polymer scaffold, but dying
before attaching to the RGD groups. Since the OPF/PEG hydrogels with 1 mM and 2 mM
PEG-RGD resulted in complete cell death, hydrogels with MAETAC were not tested for VIC
viability during encapsulation.
Alternatively, further experiments explored what might have been contributing to
hostile conditions leading to cytotoxicity. Specifically, during the synthesis of OPF, HCl is
produced as a byproduct. Any residual HCl left in the OPF product could be causing an acid
environment, unfavorable for VIC survival when exposed to the hydrogel solution. An
analysis of the OPF’s acidity was run. Additionally, the photo-initiator I2959 initially used to
form the OPF/PEG hydrogel exposed VICs to UV light for 15-minutes which is a potential
cause of cell death. A faster photo-initiator was tested for cross-linking OPF/PEG hydrogels
to reduce the time VICs are exposed to UV light. Finally, cytotoxicity of the OPF/PEG
hydrogel solution, its components, and uncross-linked material leaching out of the hydrogel
was tested on VICs.
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To investigate what could be the cause of VIC mortality during encapsulation, it was
identified that OPF could still contain residual HCl. The method for synthesizing OPF
utilizes nitrogen sparging to mobilize and remove HCl into a neutralizing base bath but there
could still be residual HCl remaining in the polymer.20 When OPF was dissolved in PBS (pH
7.4) at the concentration 20.83 wt% The pH of the PBS solution dropped 4 orders of
magnitude. A solution of PBS with a pH of 11.5 was made by adding NaOH and was shown
to counteract the acidic polymer resulting with the final hydrogel solution having a pH 7.4.
Although the pH was reset to a range that favored cell viability, this did not improve VIC
viability when exposed to the hydrogel solution for encapsulation.
In the initial OPF/PEG encapsulation of VICs experiments, the biocompatible photoinitiator I2959 was used. With I2959, to fully encapsulate the VICs in the OPF/PEG
hydrogels it required a cross-linking time of 15 minutes (UV intensity 10 mW/cm2, 365 nm).
It was believed that the UV exposure time of 15-minutes could be a potential cause of cell
death. Therefore, the photo-initiator LAP was investigated as an initiator that would speed up
the gelation process during encapsulation.53–55 Three factors, LAP concentration, UV
intensity, and cross-linking time were investigated to help improve cross-linking of the
OPF/PEG hydrogels during encapsulation (Table 4-2). Based on the sol-swell analysis, it
was found that there was no statistical difference between the UV intensity, LAP
concentration, and cross-linking time that improved cross-linking of the OPF/PEG hydrogels
(Figure 4-8). Importantly, LAP reduces the time VICs are exposed to UV light by 5x when
compared to the I2959 photo initiator.
Results of the sol-swell analysis showed that OPF/PEG hydrogels cross-linked with
LAP had similar swelling ratios and improved sol fractions when compared to the OPF/PEG
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hydrogels cross-linked with I2959 (Figure 4-8). The improved sol fraction indicates that the
LAP initiator is polymerizing more of the hydrogel solution into a polymer network.
Unfortunately, the 0.05 wt% of LAP cross-linked with 5 mW/cm2 treatment was not handled
properly and was excluded from the study. Based on the results, OPF/PEG hydrogels can be
formed with the highest cross-linking efficiency by using the LAP concentration.54
Furthermore, there is a clear reduction in cross-linking times of LAP for all concentrations
and intensities when compared to I2959 (0.05 wt%, 10 mW/cm2). Using LAP should
improve the VIC viability during encapsulation because of the reduced exposure to UV light.
Finally, components of the hydrogel solution were tested for their cytotoxicity. Specifically,
a conditioned media was made with leached products of the OPF/PEG hydrogels, the
hydrogel solution (OPF/PEG/LAP/PBS), a solution of OPF (20.83 wt%) in PBS, and a
solution of PEGDA (Mn 575) in PBS were administered to the VICs for 20-minutes,
replicating the encapsulation processing time. Results indicated that the conditioned media
and OPF solutions supported VIC culture.44,56
The 20-minute exposure to the hydrogel and PEGDA solutions were found to be
more cytotoxic and induced VIC detachment from the well plate (Figure 4-9). Also, the
VICs morphology appeared to be rounded and had lost cytoplasmic volume while producing
vesicles. Finally, unknown microspheres were seen attached to VIC membranes (Figure 410). It is hypothesized that these microspheres are PEGDA that are attaching to the cells, but
future work is needed to confirm this. It is determined that PEGDA (Mn 575) was one of the
causes of VIC cytotoxicity in the hydrogel solution and therefore a reason cells were not
surviving the encapsulation process.
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Results concluding that PEGDA (Mn 575) is cytotoxic to VICs are contradictory to
some other hydrogel platforms, though prior studies are mixed in this regard. Works that
were used to construct the positively charged OPF/PEG showed that OPF hydrogels using
PEGDA (Mn 575) as a cross-linker support cell encapsulation and growth.33,34,49,57
Additionally, PEGDA Mn 575, 700, 3400 hydrogels used to encapsulate cells were shown to
support cell encapsulation but the higher molecular weight PEGDA had increased cell
viability during the encapsulation process and through long term cell culture (14 days).58
However, other results have shown that PEGDA (Mn 575) at concentrations ranging from
0.1%-10% w/v are cytotoxic to cells when they are exposed to PEGDA for 2-hours and 24hours. Again, results showed that increasing the molecular weight and decreasing the
concentration of PEGDA improved cell viability.44,56 Based on current results, it appears that
PEGDA (Mn 575) has the latter effect of being cytotoxic to VICs in this OPF/PEG hydrogel
platform. Future iterations to improve VIC viability in OPF/PEG should consider increasing
the PEGDA cross-linker’s molecular weight.
5. Conclusion
Unlike other OPF based hydrogel systems that have been shown to support 3D
culture, the OPF used in this hydrogel platform was synthesized through a newly developed
acid scavenger-free method and did not support VIC culture.32,36,44,56,59 A few factors related
to cell mortality were explored, namely OPF pH, UV exposure time, and PEGDA (Mn 575).
It was found that the OPF still had considerable amounts of HCl. Therefore, additional postprocessing methods should explore removal of residual HCl from the polymer, rather than
offsetting the PBS pH to be basic. Generally, this will reduce the need to match the correct
basic pH of the PBS to counter the variation in acidity of the OPF per batch. To reduce the
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amount of UV exposure VICs are subjected during cross-linking, the water-soluble photoinitiator LAP has replaced the less water soluble I2959 photo-initiator. Finally, using a
PEGDA linker molecule that has a higher molecular than 575 is likely to increase the
viability of cells.44 Thus, further research to optimize the positively charged hydrogel system
should consider using higher molecular weight PEGDA, such as PEGDA Mn 3400.
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Figures

Figure 4-1. Comparison of the aortic valve with (A) healthy leaflet tissue and (B) stenotic
leaflet tissue.
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Figure 4-2. Valvular interstitial cell phenotype in vitro conditions. The morphological
characteristics of quiescent, activated, and osteoblastic VICs. Differentiation potential of VICs
for healthy and pathological states.
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Figure 4-3. The polymer network formed from photo cross-linking OPF and PEGDA with the
charged monomer MAETAC and PEG-RGD biomolecules for encapsulating VICs. Two
photo-initiators (I2959 or LAP) were explored as for creating positively charged hydrogels.
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Figure 4-4. 1H-NMR spectrum of OPF. Solvent was deuterated chloroform. Peaks (a,b)
indicate the olefin group of the fumarate monomer, (d,e) indicate the PEG (Mn 1000), (c)
indicates the ester bond formed when the PEG and fumarate react together.
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Figure 4-5. 1H-NMR of synthesized PEG-RGD biomolecule used for cell attachment.
(TOP) is the acrylate-PEG-succinimide (Mn 3400) polymer being functionalized with the
CGRGDS peptide sequence. (BOTTOM) show the Acr-PEG-RGD biomolecule
synthesized.
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Figure 4-6. Swelling ratio (A) and sol fraction (B) analysis of positively
charged hydrogels. Increasing molar concentrations of MAETAC were
photo cross-linked into OPF/PEG hydrogels and compared to an OPF/PEG
control (n = 6). *Significantly different from each other, (A) p=0.0433 and
(B) p=0.00927 (400 mM to 50 mM), p=7.04x10-5 (400 mM to OPF/PEG)
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Figure 4-7. Brightfield and fluorescent images of VICs encapsulated in
OPF/PEG hydrogels with different concentrations of PEG-RGD biomolecule
right after encapsulation. (A, B) shows VICs encapsulated in hydrogels
without any biomolecules. (C, D) are VICs encapsulated in hydrogels with 1
mM of the PEG-RGD, and (E, F) indicated VICs in hydrogels with 2 mM
concentration of PEG-RGD. (Live = Green, Dead = Red)
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Figure 4-8. Sol-swell analysis of OPF/PEG hydrogels photo cross-linked with
varying concentrations of LAP (0.03, 0.05, 0.075 wt%) and varying UV
concentrations (2, 5, 10 mW/cm2). OPF/PEG (OPF 20.87 wt%, PEGDA 4.17
wt%) hydrogels in PBS (pH 7.4), without PEG-RGD biomolecules, were photo
cross-linked with LAP. No significant differences were found between UV
intensities, LAP concentrations, or cross-linking time. (n = 4)
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Figure 4-9. Cytotoxicity of analysis of the conditioned media with leached
OPF/PEG hydrogel components, the uncross-linked hydrogel solution VICs
are suspended in for encapsulation, and the hydrogel components OPF
(20.83 wt%) and PEGDA (4.17 wt%) in PBS (pH 7.4). Exposure time to each
treatment was 20-minutes to replicate the time VICs are exposed to the
uncross-linked components before encapsulation and the initial cross-linked
OPF/PEG hydrogel. Live = Green, Dead = Red, Scale = 100 µm
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Tables
Table 4-1. The amounts of each component of the positively charged hydrogel recipe.
Indication of the different concentrations of MAETAC, and the conversion of the
MAETAC molar concentration to a weight %.

Charged Hydrogel Recipe
MAETAC
Concentration
(mM)
0
50
100
200
400

MAETAC
(wt%)
0
1.04
2.08
4.15
8.31

OPF
(wt%)
20.83
20.83
20.83
20.83
20.83
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PEGDA
(wt%)
4.17
4.17
4.17
4.17
4.17

Irgacure
(Wt%)
0.05
0.05
0.05
0.05
0.05

PBS
(Wt%)
74.95
73.91
72.87
70.8
66.64

Table 4-2. Cross-linking kinetic study parameters measured
through sol-swell of the final hydrogels. LAP concentration, UV
Intensity, and Cross-linking time was test on the OPF/PEG
hydrogels. (n = 4)
LAP Concentration
(wt%)

UV Intensity
(mW/cm2)

Cross-Linking Time
(Minutes)

0.03
0.05
0.075

2
5
10

1.0
1.5
3.0

116

References
(1) Virani, S. S.; Alonso, A.; Benjamin, E. J.; Bittencourt, M. S.; Callaway, C. W.;
Carson, A. P.; et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the
American Heart Association. Circulation 2020, 141 (9), e139–e596.
https://doi.org/10.1161/CIR.0000000000000757.
(2) Benjamin, E. J.; Blaha, M. J.; Chiuve, S. E.; Cushman, M.; Das, S. R.; Deo, R.; et al.
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart
Association. Circulation 2017, 135 (10), e146–e603.
https://doi.org/10.1161/CIR.0000000000000485.
(3) Schroer, A. K.; Merryman, W. D. Mechanobiology of Myofibroblast Adhesion in
Fibrotic Cardiac Disease. J. Cell Sci. 2015, 128 (10), 1865–1875.
https://doi.org/10.1242/jcs.162891.
(4) Merryman, W. D.; Schoen, F. J. Mechanisms of Calcification in Aortic Valve Disease:
Role of Mechanokinetics and Mechanodynamics. Curr. Cardiol. Rep. 2013, 15 (5), 355.
https://doi.org/10.1007/s11886-013-0355-5.
(5) Mabry, K. M.; Lawrence, R. L.; Anseth, K. S. Dynamic Stiffening of Poly(Ethylene
Glycol)-Based Hydrogels to Direct Valvular Interstitial Cell Phenotype in a ThreeDimensional Environment. Biomaterials 2015, 49, 47–56.
https://doi.org/10.1016/j.biomaterials.2015.01.047.
(6) Crocini, C.; Walker, C. J.; Anseth, K. S.; Leinwand, L. A. Three-Dimensional
Encapsulation of Adult Mouse Cardiomyocytes in Hydrogels with Tunable Stiffness. Prog.
Biophys. Mol. Biol. 2020, 154, 71–79. https://doi.org/10.1016/j.pbiomolbio.2019.04.008.
(7) Coombs, K. E.; Leonard, A. T.; Rush, M. N.; Santistevan, D. A.; Hedberg‐Dirk, E. L.
Isolated Effect of Material Stiffness on Valvular Interstitial Cell Differentiation. J. Biomed.
Mater. Res. A 2017, 105 (1), 51–61. https://doi.org/10.1002/jbm.a.35864.
(8) Sen, K. S.; Duarte Campos, D. F.; Köpf, M.; Blaeser, A.; Fischer, H. The Effect of
Addition of Calcium Phosphate Particles to Hydrogel-Based Composite Materials on
Stiffness and Differentiation of Mesenchymal Stromal Cells toward Osteogenesis. Adv.
Healthc. Mater. 2018, 7 (18), 1800343. https://doi.org/10.1002/adhm.201800343.
(9) Dadsetan, M.; Knight, A. M.; Lu, L.; Windebank, A. J.; Yaszemski, M. J. Stimulation
of Neurite Outgrowth Using Positively Charged Hydrogels. Biomaterials 2009, 30 (23),
3874–3881. https://doi.org/10.1016/j.biomaterials.2009.04.018.
(10) Dadsetan, M.; Pumberger, M.; Casper, M. E.; Shogren, K.; Giuliani, M.; Ruesink, T.;
Hefferan, T. E.; Currier, B. L.; Yaszemski, M. J. The Effects of Fixed Electrical Charge on
Chondrocyte Behavior. Acta Biomater. 2011, 7 (5), 2080–2090.
https://doi.org/10.1016/j.actbio.2011.01.012.
(11) De Luca, I.; Di Salle, A.; Alessio, N.; Margarucci, S.; Simeone, M.; Galderisi, U.;
Calarco, A.; Peluso, G. Positively Charged Polymers Modulate the Fate of Human

117

Mesenchymal Stromal Cells via EphrinB2/EphB4 Signaling. Stem Cell Res. 2016, 17 (2),
248–255. https://doi.org/10.1016/j.scr.2016.07.005.
(12) Hakim, J. S.; Esmaeili Rad, M.; Grahn, P. J.; Chen, B. K.; Knight, A. M.; Schmeichel,
A. M.; Isaq, N. A.; Dadsetan, M.; Yaszemski, M. J.; Windebank, A. J. Positively Charged
Oligo[Poly(Ethylene Glycol) Fumarate] Scaffold Implantation Results in a Permissive
Lesion Environment after Spinal Cord Injury in Rat. Tissue Eng. Part A 2015, 21 (13–14),
2099–2114. https://doi.org/10.1089/ten.tea.2015.0019.
(13) Kim, S.; English, A. E.; Kihm, K. D. Surface Elasticity and Charge ConcentrationDependent Endothelial Cell Attachment to Copolymer Polyelectrolyte Hydrogel. Acta
Biomater. 2009, 5 (1), 144–151. https://doi.org/10.1016/j.actbio.2008.07.033.
(14) Metwally, S.; Stachewicz, U. Surface Potential and Charges Impact on Cell Responses
on Biomaterials Interfaces for Medical Applications. Mater. Sci. Eng. C 2019, 104, 109883.
https://doi.org/10.1016/j.msec.2019.109883.
(15) Schneider, G. B.; English, A.; Abraham, M.; Zaharias, R.; Stanford, C.; Keller, J. The
Effect of Hydrogel Charge Density on Cell Attachment. Biomaterials 2004, 25 (15), 3023–
3028. https://doi.org/10.1016/j.biomaterials.2003.09.084.
(16) Scott, T. E.; Khalili, A.; Newton, B.; Warren, R.; Browe, D. P.; Freeman, J. W.
Characterization and Optimization of a Positively Charged Poly (Ethylene Glycol)Diacrylate
Hydrogel as an Actuating Muscle Tissue Engineering Scaffold. Polym. Adv. Technol. 2019,
30 (10), 2604–2612. https://doi.org/10.1002/pat.4681.
(17) Tan, F.; Liu, J.; Song, K.; Liu, M.; Wang, J. Effect of Surface Charge on Osteoblastic
Proliferation and Differentiation on a Poly(Ethylene Glycol)-Diacrylate Hydrogel. J. Mater.
Sci. 2018, 53 (2), 908–920. https://doi.org/10.1007/s10853-017-1558-8.
(18) Tan, F.; Liu, J.; Liu, M.; Wang, J. Charge Density Is More Important than Charge
Polarity in Enhancing Osteoblast-like Cell Attachment on Poly(Ethylene Glycol)-Diacrylate
Hydrogel. Mater. Sci. Eng. C 2017, 76, 330–339. https://doi.org/10.1016/j.msec.2017.03.051.
(19) Tan, F.; Xu, X.; Deng, T.; Yin, M.; Zhang, X.; Wang, J. Fabrication of Positively
Charged Poly(Ethylene Glycol)-Diacrylate Hydrogel as a Bone Tissue Engineering Scaffold.
Biomed. Mater. 2012, 7 (5), 055009. https://doi.org/10.1088/1748-6041/7/5/055009.
(20) Rush, M. N.; Coombs, K. E.; Hedberg-Dirk, E. L. Surface Chemistry Regulates
Valvular Interstitial Cell Differentiation in Vitro. Acta Biomater. 2015, 28, 76–85.
https://doi.org/10.1016/j.actbio.2015.09.031.
(21) Tibbitt, M. W.; Anseth, K. S. Hydrogels as Extracellular Matrix Mimics for 3D Cell
Culture. Biotechnol. Bioeng. 2009, 103 (4), 655–663. https://doi.org/10.1002/bit.22361.
(22) Caldwell, A. S.; Campbell, G. T.; Shekiro, K. M. T.; Anseth, K. S. Clickable Microgel
Scaffolds as Platforms for 3D Cell Encapsulation. Adv. Healthc. Mater. 2017, 6 (15),
1700254. https://doi.org/10.1002/adhm.201700254.
(23) Burdick, J. A.; Anseth, K. S. Photoencapsulation of Osteoblasts in Injectable RGDModified PEG Hydrogels for Bone Tissue Engineering. Biomaterials 2002, 23 (22), 4315–
4323. https://doi.org/10.1016/S0142-9612(02)00176-X.
118

(24) Benton, J. A.; Fairbanks, B. D.; Anseth, K. S. Characterization of Valvular Interstitial
Cell Function in Three Dimensional Matrix Metalloproteinase Degradable PEG Hydrogels.
Biomaterials 2009, 30 (34), 6593–6603. https://doi.org/10.1016/j.biomaterials.2009.08.031.
(25) Caldwell, A. S.; Aguado, B. A.; Anseth, K. S. Designing Microgels for Cell Culture
and Controlled Assembly of Tissue Microenvironments. Adv. Funct. Mater. 2020, 30 (37),
1907670. https://doi.org/10.1002/adfm.201907670.
(26) Kirschner, C. M.; Alge, D. L.; Gould, S. T.; Anseth, K. S. Clickable, Photodegradable
Hydrogels to Dynamically Modulate Valvular Interstitial Cell Phenotype. Adv. Healthc.
Mater. 2014, 3 (5), 649–657. https://doi.org/10.1002/adhm.201300288.
(27) Gould, S. T.; Anseth, K. S. Role of Cell–Matrix Interactions on VIC Phenotype and
Tissue Deposition in 3D PEG Hydrogels. J. Tissue Eng. Regen. Med. 2016, 10 (10), E443–
E453. https://doi.org/10.1002/term.1836.
(28) Gould, S. T.; Darling, N. J.; Anseth, K. S. Small Peptide Functionalized Thiol–Ene
Hydrogels as Culture Substrates for Understanding Valvular Interstitial Cell Activation and
de Novo Tissue Deposition. Acta Biomater. 2012, 8 (9), 3201–3209.
https://doi.org/10.1016/j.actbio.2012.05.009.
(29) Pedron, S.; Peinado, C.; Bosch, P.; Benton, J. A.; Anseth, K. S. Microfluidic
Approaches for the Fabrication of Gradient Crosslinked Networks Based on Poly(Ethylene
Glycol) and Hyperbranched Polymers for Manipulation of Cell Interactions. J. Biomed.
Mater. Res. A 2011, 96A (1), 196–203. https://doi.org/10.1002/jbm.a.32974.
(30) Wang, H.; Leinwand, L. A.; Anseth, K. S. Cardiac Valve Cells and Their
Microenvironment—Insights from in Vitro Studies. Nat. Rev. Cardiol. 2014, 11 (12), 715–
727. https://doi.org/10.1038/nrcardio.2014.162.
(31) Haxhinasto, K. B.; English, A. E.; Moy, A. B. Equilibrium and Non-Equilibrium
Charge-Dependent Quantification of Endothelial Cell Hydrogel Scaffolds. J. Mater. Sci.
Mater. Med. 2008, 19 (5), 1999–2008. https://doi.org/10.1007/s10856-007-3277-1.
(32) Jo, S.; Shin, H.; Mikos, A. G. Modification of Oligo(Poly(Ethylene Glycol) Fumarate)
Macromer with a GRGD Peptide for the Preparation of Functionalized Polymer Networks.
Biomacromolecules 2001, 2 (1), 255–261. https://doi.org/10.1021/bm000107e.
(33) Shin, H.; Jo, S.; Mikos, A. G. Modulation of Marrow Stromal Osteoblast Adhesion on
Biomimetic Oligo[Poly(Ethylene Glycol) Fumarate] Hydrogels Modified with Arg-Gly-Asp
Peptides and a Poly(Ethylene Glycol) Spacer. J. Biomed. Mater. Res. 2002, 61 (2), 169–179.
https://doi.org/10.1002/jbm.10193.
(34) Shin, H.; Temenoff, J. S.; Bowden, G. C.; Zygourakis, K.; Farach-Carson, M. C.;
Yaszemski, M. J.; Mikos, A. G. Osteogenic Differentiation of Rat Bone Marrow Stromal
Cells Cultured on Arg–Gly–Asp Modified Hydrogels without Dexamethasone and βGlycerol Phosphate. Biomaterials 2005, 26 (17), 3645–3654.
https://doi.org/10.1016/j.biomaterials.2004.09.050.
(35) Daly, W. T.; Knight, A. M.; Wang, H.; de Boer, R.; Giusti, G.; Dadsetan, M.; Spinner,
R. J.; Yaszemski, M. J.; Windebank, A. J. Comparison and Characterization of Multiple

119

Biomaterial Conduits for Peripheral Nerve Repair. Biomaterials 2013, 34 (34), 8630–8639.
https://doi.org/10.1016/j.biomaterials.2013.07.086.
(36) Rush, M. N.; Coombs, K. E.; Denny, C. T.; Santistevan, D.; Huynh, Q. M.; Cicotte, K.
N.; Hedberg-Dirk, E. L. Acid Scavenger Free Synthesis of Oligo(Poly(Ethylene Glycol)
Fumarate) Utilizing Inert Gas Sparging. Tissue Eng. Part C Methods 2021, 27 (5), 296–306.
https://doi.org/10.1089/ten.tec.2021.0027.
(37) Johnson, C. M.; Hanson, M. N.; Helgeson, S. C. Porcine Cardiac Valvular
Subendothelial Cells in Cnlture: Cell Isolation and Growth Characteristics. J. Mol. Cell.
Cardiol. 1987, 19, 1185–1193.
(38) Benton, J. A.; DeForest, C. A.; Vivekanandan, V.; Anseth, K. S. Photocrosslinking of
Gelatin Macromers to Synthesize Porous Hydrogels That Promote Valvular Interstitial Cell
Function. Tissue Eng. Part A 2009, 15 (11), 3221–3230.
https://doi.org/10.1089/ten.tea.2008.0545.
(39) Lam, J.; Lu, S.; Meretoja, V. V.; Tabata, Y.; Mikos, A. G.; Kasper, F. K. Generation of
Osteochondral Tissue Constructs with Chondrogenically and Osteogenically
Predifferentiated Mesenchymal Stem Cells Encapsulated in Bilayered Hydrogels. Acta
Biomater. 2014, 10 (3), 1112–1123. https://doi.org/10.1016/j.actbio.2013.11.020.
(40) Ma, J.; Yang, F.; Both, S. K.; Kersten-Niessen, M.; Bongio, M.; Pan, J.; Cui, F.-Z.;
Kasper, F. K.; Mikos, A. G.; Jansen, J. A.; van den Beucken, J. J. J. P. Comparison of CellLoading Methods in Hydrogel Systems. J. Biomed. Mater. Res. A 2014, 102 (4), 935–946.
https://doi.org/10.1002/jbm.a.34784.
(41) Wang, H.; Liu, Z.; Li, D.; Guo, X.; Kasper, F. K.; Duan, C.; Zhou, J.; Mikos, A. G.;
Wang, C. Injectable Biodegradable Hydrogels for Embryonic Stem Cell Transplantation:
Improved Cardiac Remodelling and Function of Myocardial Infarction. J. Cell. Mol. Med.
2012, 16 (6), 1310–1320. https://doi.org/10.1111/j.1582-4934.2011.01409.x.
(42) Lam, J.; Clark, E. C.; Fong, E. L. S.; Lee, E. J.; Lu, S.; Tabata, Y.; Mikos, A. G.
Evaluation of Cell-Laden Polyelectrolyte Hydrogels Incorporating Poly(l-Lysine) for
Applications in Cartilage Tissue Engineering. Biomaterials 2016, 83, 332–346.
https://doi.org/10.1016/j.biomaterials.2016.01.020.
(43) Kinard, L. A.; Kasper, F. K.; Mikos, A. G. Synthesis of Oligo(Poly(Ethylene Glycol)
Fumarate). Nat. Protoc. 2012, 7 (6), 1219–1227. https://doi.org/10.1038/nprot.2012.055.
(44) Shin, H.; Temenoff, J. S.; Mikos, A. G. In Vitro Cytotoxicity of Unsaturated
Oligo[Poly(Ethylene Glycol) Fumarate] Macromers and Their Cross-Linked Hydrogels.
Biomacromolecules 2003, 4 (3), 552–560. https://doi.org/10.1021/bm020121m.
(45) Underhill, G. H.; Chen, A. A.; Albrecht, D. R.; Bhatia, S. N. Assessment of
Hepatocellular Function within PEG Hydrogels. Biomaterials 2007, 28 (2), 256–270.
https://doi.org/10.1016/j.biomaterials.2006.08.043.
(46) Li, C. Y.; Wood, D. K.; Hsu, C. M.; Bhatia, S. N. DNA-Templated Assembly of
Droplet-Derived PEG Microtissues. Lab. Chip 2011, 11 (17), 2967–2975.
https://doi.org/10.1039/C1LC20318E.

120

(47) Seeto, W. J.; Tian, Y.; Lipke, E. A. Peptide-Grafted Poly(Ethylene Glycol) Hydrogels
Support Dynamic Adhesion of Endothelial Progenitor Cells. Acta Biomater. 2013, 9 (9),
8279–8289. https://doi.org/10.1016/j.actbio.2013.05.023.
(48) Peter, M.; Tayalia, P. An Alternative Technique for Patterning Cells on Poly(Ethylene
Glycol) Diacrylate Hydrogels. RSC Adv. 2016, 6 (47), 40878–40885.
https://doi.org/10.1039/C6RA08852J.
(49) Shin, H.; Quinten Ruhé, P.; Mikos, A. G.; Jansen, J. A. In Vivo Bone and Soft Tissue
Response to Injectable, Biodegradable Oligo(Poly(Ethylene Glycol) Fumarate) Hydrogels.
Biomaterials 2003, 24 (19), 3201–3211. https://doi.org/10.1016/S0142-9612(03)00168-6.
(50) Carberry, B. J.; Rao, V. V.; Anseth, K. S. Phototunable Viscoelasticity in Hydrogels
Through Thioester Exchange. Ann. Biomed. Eng. 2020, 48 (7), 2053–2063.
https://doi.org/10.1007/s10439-020-02460-w.
(51) Grim, J. C.; Aguado, B. A.; Vogt, B. J.; Batan, D.; Andrichik; Schroeder, M. E.;
Gonzalez-Rodriguez, A.; Yavitt, F. M.; Weiss, R. M.; Anseth, K. S. Secreted Factors From
Proinflammatory Macrophages Promote an Osteoblast-Like Phenotype in Valvular
Interstitial Cells. Arterioscler. Thromb. Vasc. Biol. 2020, 40 (11), e296–e308.
https://doi.org/10.1161/ATVBAHA.120.315261.
(52) Hern, D. L.; Hubbell, J. A. Incorporation of Adhesion Peptides into Nonadhesive
Hydrogels Useful for Tissue Resurfacing. J. Biomed. Mater. Res. 1998, 39 (2), 266–276.
https://doi.org/10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B.
(53) McCall, J. D.; Anseth, K. S. Thiol–Ene Photopolymerizations Provide a Facile Method
To Encapsulate Proteins and Maintain Their Bioactivity. Biomacromolecules 2012, 13 (8),
2410–2417. https://doi.org/10.1021/bm300671s.
(54) Fairbanks, B. D.; Schwartz, M. P.; Bowman, C. N.; Anseth, K. S. Photoinitiated
Polymerization of PEG-Diacrylate with Lithium Phenyl-2,4,6-Trimethylbenzoylphosphinate:
Polymerization Rate and Cytocompatibility. Biomaterials 2009, 30 (35), 6702–6707.
https://doi.org/10.1016/j.biomaterials.2009.08.055.
(55) Fairbanks, B. D.; Singh, S. P.; Bowman, C. N.; Anseth, K. S. Photodegradable,
Photoadaptable Hydrogels via Radical-Mediated Disulfide Fragmentation Reaction.
Macromolecules 2011, 44 (8), 2444–2450. https://doi.org/10.1021/ma200202w.
(56) Temenoff, J. S.; Shin, H.; Conway, D. E.; Engel, P. S.; Mikos, A. G. In Vitro
Cytotoxicity of Redox Radical Initiators for Cross-Linking of Oligo(Poly(Ethylene Glycol)
Fumarate) Macromers. Biomacromolecules 2003, 4 (6), 1605–1613.
https://doi.org/10.1021/bm030056w.
(57) Temenoff, J. S.; Athanasiou, K. A.; Lebaron, R. G.; Mikos, A. G. Effect of
Poly(Ethylene Glycol) Molecular Weight on Tensile and Swelling Properties of
Oligo(Poly(Ethylene Glycol) Fumarate) Hydrogels for Cartilage Tissue Engineering. J.
Biomed. Mater. Res. 2002, 59 (3), 429–437. https://doi.org/10.1002/jbm.1259.

121

(58) Pan, J.; Yung Chan, S.; Common, J. E. A.; Amini, S.; Miserez, A.; Birgitte Lane, E.;
Kang, L. Fabrication of a 3D Hair Follicle-like Hydrogel by Soft Lithography. J. Biomed.
Mater. Res. A 2013, 101 (11), 3159–3169. https://doi.org/10.1002/jbm.a.34628.
(59) Coombs, K. Designing Synthetic Environments to Control Valvular Interstitial Cells In
Vitro, University of New Mexico, Health Sciences Center, 2018.

122

Chapter 5
Poly(1,2-Butylene Fumarate) and Poly(1,3-Butylene Fumarate)
Characterization for Use in Tissue Engineering
Christian T. Denny1,2, Jasmine Jackson3, Charles Easterling, PhD4, Elizabeth L. HedbergDirk, PhD1-3, Christina Salas, PhD1,5,6

1

Center for Biomedical Engineering, University of New Mexico, Albuquerque, New
Mexico, USA.

2

Biomedical Engineering Graduate Program, University of New Mexico, Albuquerque,
New Mexico, USA.
3

Department of Chemical and Biological Engineering, University of New Mexico,
Albuquerque, New Mexico, USA.

4

Center for Integrated Nanotechnologies, Sandia National Laboratories/Los Alamos
National Laboratory, Albuquerque, New Mexico, USA.

5

Department of Orthopaedics and Rehabilitation, The University of New Mexico Health
Sciences Center, Albuquerque, New Mexico

6

Department of Mechanical Engineering, The University of New Mexico, Albuquerque,
New Mexico

123

Abstract
Current methods to treat ligament tears range from primary ligament repair to full
reconstruction of the damaged area but fail to replicate the biomechanical and biochemical
gradients found within the bone-ligament (BL) interface. Advances in biomaterials and
biomolecule research have created mechanical and biochemical gradients like the bone phase
but research into biomaterials that replicate the whole BL enthesis is needed. Poly(butylene
fumarate) is linear polyester that has unsaturated double bonds available for crosslinking.
This material can be systematically engineered to have varying material properties through
the selection of the butylene monomer. This work synthesizes poly(1,2-butylene fumarate)
(1,2-PBF) and poly(1,3-butylene fumarate) (1,3-PBF) and developed them into photo
crosslinkable solutions and cast them into films. Through nuclear magnetic resonance (NMR)
and Fourier-transform infrared spectroscopy (FTIR) both PBF polymers were shown to be
successfully synthesized. Gel permeation chromatography revealed that 1,2-PBF had a
number-average molecular weight (Mn) of 1,380 ± 127 g/mole, weight-average molecular
weight (Mw) of 2,139 ± 199 g/mole, polydispersity index (PDI) of 1.55 ± 0.06, and a glass
transition temperature (Tg) of -20.0°C. Correspondingly, 1,3-PBF had a Mn of 3,315 ± 116
g/mole, Mw of 6,618 ± 139 g/mole, PDI of 2.00 ± 0.04, and a Tg of -27.5°C. The FTIR
spectrum of both PBF films showed a high degree of crosslinking. It was also found that 1,3PBF was stiffer than 1,2-PBF. Further research will aim to 3D bioprint the materials into
porous scaffolds and test biocompatibility.
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1. Introduction
In the United States, sports and recreational-related sprains and strains account for
4,262,000 injuries annually.1 Sprains and strains stretch and, potentially, tear tendons and
ligaments causing instability, pain, and loss of mobility in joints. Current surgical approaches
aim to restore the biomechanical function of the torn ligament through primary ligament
repair and pinning or ligament reconstruction with screw fixation, tendon, or bone-ligamentbone (BLB) grafts.2–6 Commonly used reconstruction material options are typically classified
as autograph or non-autograph. The autographic material is beneficial because it matches
physiological structure and mechanical strength but can lead to donor-site morbidity and
limited donor tissue.7 Non-autograph options reduce the chance of donor-site morbidity but
lack the mechanical and biochemical cues needed to restore bone and ligament. Generally,
failures of reconstructive materials occur at the bone-ligament (BL) interface. This is due to
the high-stress concentration at the interface and inadequate regeneration of the enthesis.8–15
Due to these problems, there is a need for treatment options that aim to restore the
biomechanical and biochemical function of the BL interface while simultaneously allowing
tissue regeneration.16–19
In an attempt to reduce BL reconstructive failures, BLB constructs are whole
ligament implants that are either taken from donor tissue or fabricated ex situ and focus on
long-term regeneration of the BL interface.20–22 Precisely, BLB constructs aim to recapitulate
the biomechanical and biochemical gradients found in the BL milieu to restore natural
function to the joint. Replicating the interface encompasses a complex and dynamic
mechanical gradient starting at the highly compressive strong bone phase and transitioning to
the highly elastic ligament phase.15,23,24 A similar complex biochemical gradient can be found
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too. Within the interface, the BL enthesis is a short transitional phase that adjoins the bone
and ligament phases. The enthesis starts with long type I collagen fibers inserted into
uncalcified-fibrocartilage, then progresses into mineralized-fibrocartilage, and finally ends in
bone material.18,25 Current natural BLB implants maintain these biomechanical and
biochemical gradients but are limited by tissue availability and donor-site morbidity.20,21
Some synthetically fabricated BLB alternatives have been developed but do not accurately
replicate the natural BL environment. Therefore, there has been a considerable amount of
research in further developing synthetic BLB devices.
There has been the successful development of scaffolds with synthetic polymers that
have similar mechanical gradients as the bone and ligament environment and have been
shown to support cell growth and differentiation of mesenchymal stem cells but there is a
need for biomaterials that replicate the mechanical properties of the BL enthesis.23,24
Additionally, the incorporation of bioactive molecules into phases of the synthetic BLB has
been used to make biochemical gradients that compartmentally differentiate cells types in
their bone, fibrocartilage, and ligament phenotypes which are biocompatible and functional
in vivo.16–18,24,26,27 These results demonstrate the need to combine the biomaterial and
bioactive components into architecturally complex BLB devices that accurately replicate the
biomechanical, biochemical, and material organization found in the bone, fibrocartilage, and
ligament for regeneration of the BL interface.
Advances in additive manufacturing have made it possible to mimic the material
architecture while maintaining the biomechanical and biochemical gradients found in the BL
interface. Three-dimensional (3D) bioprinting is a commonly used manufacturing technique
that can use a variety of biomaterials to create porous bone constructs with varying degrees
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of mechanical strength and osteoinductive properties.24,28–30 Electrospinning is another
additive manufacturing technique that can make nanoscale fibers out of biomaterials in a
variety of patterns. A specific type of electrospinning, near-field electrospinning, makes
nanoscale fibers but has the added advantage of controllable fiber deposition. This allows for
systematic fiber deposition into geometries that are optimal for ligament tensile strength and
fibroblast growth.26,31 A new hybrid bioprinting system has been developed that combines
3D bioprinting and near-field electrospinning. This hybrid printer has the benefit of printing
and spinning biomaterials to create the BLB composite construct with a porous bone phase
and filamentous ligament phase.16,24,26,27,31 This technique is promising for making highly
detailed constructs with architecture that replicates the material organization of the BL
interface. While this 3D printing can make high fidelity constructs, new biomaterials and
bioink solutions are needed to replicate the BL interface more accurately, specifically the
enthesis, and stimulate tissue regeneration.
Of interest are materials that are designed specifically for bone and mineralized
fibrocartilage. Some biomaterials that have been shown to grow bone tissue consist of
ceramics (hydroxyapatite, calcium phosphate, and bioactive glass) and synthetic polymers
(polycaprolactone, poly(lactic-co-glycolic acid), polymethyl-methacrylate, poly(propylene
fumarate).16,23,24,26,32,33 Recently Lui et al. have 3D printed a multiphasic BLB scaffold out of
medical-grade polycaprolactone and showed that the scaffold demonstrated
compartmentalized tissue regeneration of the bone and ligament region, while maintaining
structural integrating in vivo.16,17 A hybrid bone tissue scaffold was fabricated using 3D
printing and electrospinning of poly(ethylene oxide terephthalate)-poly(butylene
terephthalate) and coated with calcium phosphate. These scaffolds were found to support
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stem cell attachment, proliferation, and differentiation into osteogenic cells.27 Furthermore,
polycaprolactone, hydroxyapatite, and β-tricalcium phosphate were combined and 3D printed
into porous scaffolds that had mechanical and biochemical gradients. Through these
gradients, it was shown that mesenchymal stem cells could attach and differentiate into
osteoblasts.23,24
Poly(propylene fumarate) (PPF) is a synthetic fumarate-based polymer that has been
used extensively in bone tissue engineering. The linear polyester is favored for its multiple
unsaturated double bonds that can be used for photo or thermal crosslinking and its ability to
biodegrade through hydrolysis.32,34–39 Likewise, PPF has been shown to have optimal
mechanical properties for 3D bioprinting stiff porous constructs that have similar mechanical
strength as bone tissue.23,29,32 The mechanical stiffness and surface chemistry have also been
shown to support osteoblast attachment and growth over extended culture periods.28,34 When
combined with bioactive ceramics and growth factors, PPF has been considered a suitable
material for building BLB scaffolds.32,40 Unfortunately, PPF has an extended degradation
time which is not conducive to scaffold remodeling and bone regeneration.41 There is a need
for tailored materials that have similar properties as PPF and improve tissue
regeneration.23,24,33
Poly(butylene fumarate) (PBF) is a similar fumarate-based polymer that has potential
as a 3D printable bone material. Like PPF, PBF contains unsaturated double bonds and is
hydrolytically biodegraded, but unlike PPF, it can be chemically engineered to have different
material properties through its butylene group. It is believed the additional carbon in the
butane and the presence of a side group, like the ethyl group in 1,2-butane, will alter the
material properties of the polymer. Creating a looser polymer network compared to PPF, and
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when crosslinked, causes altered mechanical and material properties. Notably, a looser
network allows for increasing degradation to a rate that is favorable for bone
regeneration.41,42 Poly(butylene fumarate) has been previously synthesized with different
conformations of butane (1,3-butane, 1,4-butane) and in co-polymers for tissue engineering
purposes.41–45 Further investigation into PBF with different butylene conformations is of
interest for developing additional biomaterials for tissue engineering the BL milieu.
We recently synthesized poly(1,2-butylene fumarate) (1,2-PBF) and poly(1,3butylene fumarate) (1,3-PBF) and are interested in characterizing the polymers for use in
bone tissue engineering (Schematic 5-1). To date, poly(1,2-butylene fumarate) (1,2-PBF) has
not been published as a biomaterial for any tissue engineering applications and is being
investigated as a new biomaterial. In this work both polymers will be synthesized,
characterized, and made into photo crosslinkable solutions, and cast into films to study the
polymer's ability to form polymer networks.
2. Materials and Methods
2.1 Poly(Butylene Fumarate) Synthesis
Poly(1,2-butylene fumarate) and poly(1,3-butylene fumarate) were synthesized via an
acid free polycondensation reaction.46,47 Fumaryl chloride (FuCl, TCI, F0152) was distilled
before use. Briefly, one mole of 1,2-butanediol (1,2-BD) or 1,3-butanediol (1,3-BD) was
dissolved in dichloromethane (DCM, VWR, BDH1113) in a 3-neck round bottom flask. The
reaction was maintained under a nitrogen blanket to impede oxygen inhibition of the
polymerization. The solution was stirred vigorously while a 1:1 molar ratio of FuCl to
butanediol (BD) was added dropwise over 4-6 hours. Throughout the reaction, removal of
hydrochloric acid (HCl) byproduct was accomplished by nitrogen gas sparging using a fine
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fritted gas dispersion tube (Chemglass, CG-203-01) at a flow rate of 2.0 SCFH. The removed
HCl was neutralized in a 1 M NaOH (VWR, 221465) in ethanol (Koptec, V1001). The
reaction was allowed to progress for 48-hours under continual sparging with periodic DCM
refills to maintain a constant level within the reaction vessel. At the completion of the
reactions, DCM was removed via rotary evaporation (Buchi, R-215). The PBF was then
resuspended in chloroform and washed with deionized water 3 times. The polymer was dried
with a brine wash followed by the addition of magnesium sulfate to the polymer solution to
completely remove residual water. The solution was vacuum filtered to remove the
magnesium sulfate. The solvent was removed via rotary evaporation and all polymers were
stored at -20°C under dark conditions.
2.2 Chemical and Material Properties of Poly(Butylene Fumarate)
Proton and carbon nuclear magnetic resonance (1H-NMR, 13C-NMR) imaging was
performed to assess the chemical structure of both PBF polymers using the Avance III
Solution 300 (300 MHz, Bruker, Massachusetts). Characterization was performed using
borosilicate NMR tubes (5 mm diameter, Wilmad, New Jersey) with deuterated chloroform
(Millipore Sigma, Germany) as the solvent. The molecular weight of the polymers was
analyzed using gel permeation chromatography (GPC) on the Agilent 1260 Infinity II (Santa
Clara, CA) with two Agilent PLgel 5 μm MIXED-C columns running in tetrahydrofuran
(THF, 1.0 mL/min at 30oC) with a polystyrene standard (Agilent). Differential scanning
calorimetry (DSC) was performed on the STA 449 F1 Jupiter (NETZSCH, Germany) under
nitrogen atmosphere to determine glass transition temperature. Samples were cooled at a 5
K/min rate and heated at a rate of 3 K/min, respectively.
2.2 Poly(Butylene Fumarate) Films
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To create polymerization solutions, PBF was mixed with a diethyl fumarate solution
(DEF, Millipore Sigma, D95654) in a 9:1 weight ratio of PBF to DEF solution. To make the
DEF solution, 0.3 wt% of photo-initiator phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide
(BAPO, Millipore Sigma, 511447) was dissolved in 9.7 wt% of DEF and minimal (500μL:1g
BAPO) chloroform (Millipore Sigma, CX1055).30,35 The final PBF:DEF solution was placed
in a vacuum oven for 24-hours to remove residual chloroform.
The solutions were then injected between two glass slides held 1 mm apart with a
Teflon spacer. The mold was placed in a UV Crosslinker box (Analytik Jena, CL-1000) for
30-minutes (365nm, 2 mW/cm2). Crosslinked films were removed from the molds and used
for analyses.
2.3 Characterization of Crosslinked Poly(Butylene Fumarate)
Fourier transform infrared (FTIR) spectra were obtained from 1,2-PBF and 1,3-PBF
polymers along with associated crosslinked films on a Bruker IFS 66vS (Bruker Optik,
Germany). All samples were analyzed using a grazing angle attenuated total reflectance
(GATR) with a fixed 65o incident angle on a hemispherical germanium crystal (Harrick
Scientific Product Inc., Pleasantville, NY). 256 scans per sample were collected at a 2 cm-1
resolution from 4000 cm-1 to 700 cm-1 using liquid nitrogen cooled MCT detector.
2.4 Statistics
All measured data were reported as average ± standard deviation. Statistics were
performed using Microsoft Excel.
3. Results
3.1 Nuclear Magnetic Resonance Spectroscopy
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Poly(1,2-butylene fumarate) and poly(1,3-butylene fumarate) were successfully
synthesized using a polycondensation reaction that polymerized 1,2-BD or 1,3-BD with FuCl
(Schematic 5-1). The molecular structure of PBFs was confirmed using 1H-NMR and 13CNMR analyses. Representative peaks for the fumarate group were present at 6.5-7.0 ppm on
the 1H-NMR spectra (Figure 5-1). The ethylene peaks associated with the 1,2-butylene were
located at 0.8-1.1 ppm and 1.4-1.9 ppm. While the 1,3-butylene methyl peaks were located at
1.0-1.4 ppm and 1.6-2.2 ppm.1,2 Moreover, it was observed that BD peaks shift downfield
after polymerization indicating increased shielding of the butane protons in the PBF polymer.
In the 13C-NMR spectrum of the 1,2-PBF, three carbon peaks appear for the BD
group at 72-76 ppm (CH), 64-67 ppm (CH2-O), 23-25 ppm (CH2), and 8-10 ppm (CH3).
Additionally, BD groups in the 1,3-PBF spectrum appear at 68-72 ppm (CH), 60-65 ppm
(CH2-O), 33-40 ppm (CH2), and 18-24 ppm (CH3). The fumaric group can be found at peaks
132-136 ppm (C=C) and 163-166 ppm (C=O) for both 1,2- and 1,3-PBF spectra (Figure 52).38,43,48
3.2 Fourier-Transform Infrared Spectroscopy
Upon further chemical analysis of the PBF polymers, FTIR also confirmed that 1,2PBF and 1,3-PBF were successfully synthesized through the presence of characteristic bonds.
The unsaturated double bond peaks at 979 cm-1 (C-H, Bending), 1644 cm-1 (C=C,
Stretching), and 2973 (C-H, Stretching) indicated the presence of the fumarate group (Figure
5-3). 43,49 Peaks at 1157 cm-1 (C-O, Stretching) and 1297 cm-1 (C-C, Stretching) also
indicated the presence of the butane group (Table 5-2).50 Finally, peaks located at 1157 cm-1
(C-O, Stretching) and 1725 cm-1 (C=O, Stretching) confirm that esterification of butane and
fumarate has occurred.
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3.3 Molecular Weight and Glass Transition Temperature
Molecular weight analysis showed that 1,2-PBF has a number-average molecular
weight (Mn) of 1,380 ± 127 g/mole, weight-average molecular weight (Mw) of 2,139 ± 199
g/mole, and a polydispersity index (PDI) of 1.55 ± 0.06 (Table 5-1).34,35 While 1,3-PBF had
a Mn of 3,315 ± 116 g/mole, Mw of 6,618 ± 139 g/mole, and a PDI of 2.00 ± 0.04. Based on
the Mw of 1,2-PBF and 1,3-PBF the double bonds per molecule are 11-14 and 38-40,
respectively. Additionally, the glass transition temperatures were found to be -20.0°C for 1,2PBF and -27.5°C for 1,3-PBF (Table 5-1).43,44,49
3.4 Characterization of Poly(Butylene Fumarate) Films
Poly(butylene fumarate) was combined with diethyl fumarate and BAPO and
crosslinked through UV initiation into hard plastic films.30,35 Comparison of FTIR spectrums
of 1,2-PBF and 1,3-PBF polymers to their corresponding films was used to evaluate the
degree of crosslinking. Specifically, the absence of the fumarate double bond peak at 1644
cm-1 (C=C, Stretching) was used to confirm that the unsaturated bonds were indeed used
during UV crosslinking to form the polymer network. The 1,2-PBF polymer has a distinct
peak at 1644 cm-1 peak but was not present in the crosslinked 1,2-PBF film (Figure 5-4).
Correspondingly, the 1,3-PBF and the crosslinked 1,3-PBF film showed a similar result,
indicating most of the fumarate doubles bonds were used during the UV crosslinking process.
There are differences in material properties when handled. The 1,2-PBF was found to be
more flexible and 1,3-PBF scaffolds were stiffer.
4. Discussion
The bone-ligament interface is a complex structure made up of hard and soft
materials that adapt to high compressive tensile loads to maintain stability. It consists of a
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complex biomechanical and biochemical gradient. Tissue engineering has aimed to mimic
these mechanical and chemical gradients to develop a device that can be used for studying
and treating damaged ligaments.26 To accomplish making a complex interface, such as the
bone-ligament, new biomaterials and methods are needed. As such, this work has
investigated PBF’s potential as a biomaterial for use as a bioink to 3D print the bone phase.
Specifically, two variations of PBF were synthesized using 1,2-BD and 1,3-BD (Schematic
5-1).43,44,46 Through 1H-NMR and 13C-NMR analyses it was confirmed that butanediol
successfully reacted with FuCl (Figures 5-1 and 5-2).38,43,44,48 Additionally, there were
residual peaks associated with butanediol suggesting that there was butanediol left in the
final product of both PBF polymers. Further post-processing steps, like size-exclusion
chromatography, should be tested for purifying the final PBF product. In a 1H-NMR
comparison of the corresponding butanediol to PBF, it was found that butane-associated
peaks, like the methyl and ethyl groups, shift downfield after polymerization. This can be
explained by butane protons being more shielded by the fumarate groups.
Additionally, 1H-NMR peak comparison of 1,2-PBF showed that the olefin peak (6.570 ppm) was half of the ethyl peaks (0.8-1.1 ppm) (Figure 5-1). Theoretically, a 1:1 molar
ratio of BD:FuCl should produce the comparable peak intensities of the olefin to ethyl peaks.
It is hypothesized that the discrepancy in the olefin peak intensity is again contributed to
reduced polymerization during the synthesis. The residual unreacted FuCl is removed from
the final 1,2-PBF product during the washing steps. When FuCl is neutralized and washed
out of the polymer. Conversely, 1,2-BD is miscible in water and is retained in the polymer
solution throughout the post-processing steps. The presence of butanediol in the final PBF
polymer would show up as additional peaks in the NMR spectrum, which can be seen in the
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1

H-NMR and 13C-NMR spectra (Figures 5-1 and 5-2). Further purification steps should be

investigated to completely remove unreacted butanediol from the final 1,2-PBF polymer.
FTIR analyses also confirmed the polymerization of butanediol with FuCl through the
presence of the ester bond stretching peaks (Figures 5-3 and Table 5-2).43,44,50 Although 1,2PBF and 1,3-PBF spectra showed characteristic PBF peaks, they lacked a broad hydroxyl
peak found past 3000 cm-1. The absences of these peaks suggest that a large fraction of PBF
molecules do not contain hydroxyl end groups, but rather carboxyl end groups. A 1:1 molar
ratio of BD:FuCl theoretical would have a mixture of hydroxyl and carboxyl terminated
polymers in one sample. Ideally, the hydroxyl-terminated end groups are preferred due to the
acidity of the carbonyl. Altering the BD:FuCl molar ratio to have more butanediol would
increase the chances of more hydroxyl-terminated PBF molecules.34,51,52
The material properties associated with polymers are correlated to their molecular
weight. To investigate 1,2-PBF and 1,3-PBF as potential biomaterials for 3D printing
applications their molecular weights were analyzed. The 1,2-PBF had a Mw of 2,139 ± 199
g/mole, which is ~3 times smaller than the molecular weight of 1,3-PBF 6,618 ± 139 g/mole
for the same reaction time and conditions (Table 5-1).35,43,44 The difference in molecular
weight could be contributed to steric hindrance during synthesis, wherein 1,2-BD’s hydroxyl
groups were more sterically hindered, thereby reducing the chances of polymerization with
FuCl. The resulting difference in molecular weight affected the viscosity and Tg of the PBF
polymers. It was visually observed that 1,3-PBF had a higher viscosity than the 1,2-PBF at
room temperature, and 1,2-PBF had a higher Tg -20°C than the 1,3-PBF -27°C (Table 51).43,44,49 It was found that the crosslinked films of PBF had different stiffnesses. Upon visual
handling, the 1,2-PBF films were more flexible than the 1,3-PBF scaffolds. The differences
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in material properties are due to molecular weight and the BD structure in the polymer
backbone.53 Particularly, 1,2-PBF contains 11-14 double bonds per molecule compared to
38-40 double bonds that 1,3-PBF contains. The amount of double bonds per molecule, in
turn, affects the organization of the polymer network during UV crosslinking.35 Moreover,
the butane side group also contributes to the polymer packing. The 1,2-BD group has an
ethyl side group that reduces polymer chain packing and the methyl group in 1,3-PBF allows
for a tighter polymer network causing the bulk properties to be stronger.41
Photo initiation is a popular method for starting free radical polymerization during 3D
printing. Therefore 1,2-PBF and 1,3-PBF were made into UV crosslinkable solutions using
phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide.30,35 It was shown that both 1,2-PBF and
1,3-PBF solutions were cast into films that fully crosslinked after 30-minutes of exposure to
2 mW/cm2 UV light (365 nm). To analyze the degree of crosslinking of the films, FTIR
spectrums were taken, and the unsaturated double bond peaks of the polymer and crosslink
films were compared. A distinct peak at 1644 cm-1 that is assigned to the fumarate double
bond can be observed in 1,2-PBF and 1,3-PBF polymer FTIR spectrums, but, after
crosslinking, the film spectrums show a significant reduction in intensity, suggesting a high
degree of crosslinking is occurring (Figure 5-4).
5. Conclusions
Through chemical and material analysis it was shown that 1,2-PBF and 1,3-PBF were
successfully synthesized into a linear polyester polymer with multiple functional double
bonds. It was found that 1,2-PBF differed from 1,3-PBF in molecular weight and glass
transition temperature. Polymers were UV crosslinked into films. The differences in
molecular weight and chemical structure of butane in 1,2-PBF and 1,3-PBF polymers
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translated into differing material properties, where 1,2-PBF films were found to be more
flexible than the 1,3-PBF scaffolds. Results show that l,2-PBF, and 1,3-PBF are promising
biomaterials for future bone tissue engineering and 3D bioprinting applications. Further
investigation into the printability of the PBF solution is necessary for future use in 3D
printing the bone phase of the bone-ligament device.
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Schematic

Schematic 5-1. Set-up for synthesizing PBF using an acid free, polycondensation reaction
(A). Chemical reaction for making both types of PBF (1,2-PBF and 1,3-PBF) from FuCl
and 1,2-BD or 1,3-BD, utilizing nitrogen sparging (B). Adapted from (46)
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Figures

Figure 5-1. Proton NMR of 1,2-PBF (Top) and 1,3-PBF (Bottom). In-laid spectrum are
proton NMR of corresponding butanediol only.
139

Figure 5-2. Carbon NMR of 1,2-PBF (Top) and 1,3-PBF (Bottom). Both types of PBF were
run in CDCl3 solvent (δ 77.0, triplet).
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Figure 5-3. Fourier-Transform infrared spectrum of 1,2-PBF and 1,3-PBF polymer and the
corresponding 1,2-PBF and 1,3-PBF scaffolds.
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Figure 5-4. Fumarate peak 1644 cm-1 (C=C, Stretching) comparison of (A) 1,2-PBF
polymer vs crosslinked scaffold and (B) 1,3-PBF polymer vs crosslinked scaffold.
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Tables
Table 5-1. The molecular weight of synthesized 1,2-PF and 1,3-PBF with corresponding
polydispersity index. (n = 4)
Polymer

Tg
(°C)

Mn
(g/mole)

Mw
(g/mole)

PDI

1,2-PBF

-20.0

1380 ± 127

2139 ± 199

1.55 ± 0.06

7-9 (Mn)

11-14 (Mw)

1,3-PBF

-27.5

3315 ± 116

6618 ± 139

2.00 ± 0.04

18-20 (Mn)

38-40 (Mw)
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Double Bonds per
Molecule

Table 5-2. FTIR spectral peaks of poly(butylene fumarate) polymers and scaffolds.50
Spectral Response

Peak Position

C—H bending of trans CH=CH for PBF

979 cm-1

C—O stretching of ester linkage for BD

1157 cm-1

C—C stretching for BD

1297 cm-1

—CH3 asymmetric bending for BD

1469 cm-1

C=C stretching of —CH=CH— for PBF

1688 cm-1

C=O stretching of ester for PBF and BD

1725 cm-1

C—H

2878 cm-1

C=CH2

2973 cm-1
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Chapter 6
Conclusions
In the last 20 years, tissue engineering has seen rapid development in new
biomaterials, cell types, and signaling molecules through the assimilation of concepts from
related fields of study, like materials science, rapid prototyping, nanotechnology, and cell
biology.1 Particularly, in the field of biomaterials, there have been advances in smart
biomaterials and additive manufacturing that have given engineers the ability to design nanoand microscale-scale scaffolds to replicate the native tissue organization and respond to their
environments. Within the field of biomaterials, fumarate-based polymers have been
foundational in the development of bone, cartilage, and soft tissue engineering.
Poly(propylene fumarate) (PPF) and oligo(poly(ethylene glycol) fumarate) (OPF)
have been studied extensively for tissue engineering and drug delivery.2,3 The linear synthetic
polymers are favored for their ability to chemically crosslink into cell scaffolds and
subsequently biodegrade. Moreover, OPF is a hydrophilic polymer that forms hydrogels
when crosslinked, ideal for creating soft tissue scaffolds, and PPF is a hydrophobic polymer
that forms stiff plastics, ideal for bone tissue. In this work, two fumarate-based polymers
were investigated for tissue engineering applications. First, OPF was developed into a
hydrogel platform that contains positively charged monomers and cell attachment
biomolecules. This charged hydrogel platform was used to encapsulate valvular interstitial
cells (VIC) to study how a positively charged environment affected the VIC phenotype.
Second, poly(butylene fumarate) (PBF) was synthesized using 1,2-butanediol and 1,3butanediol to make two variations of PBF, poly(1,2-butylene fumarate) (1,2-PBF) and
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poly(1,3-butylene fumarate) (1,3-PBF). The chemical and material properties of 1,2-PBF and
1,3-PBF were then characterized for use as a bone scaffold.
Specific Aim 1: Fabricate a synthetic OPF-based hydrogel with tunable positively charged
densities.
The first fumarate-based polymer explored was OPF. This polymer is made with
poly(ethylene glycol) which gives OPF hydrophilic and bioinert properties. These properties
are desired for making soft tissue models and reducing the number of environmental
variables when testing cell-material interactions. Based on the properties, OPF was used as a
base polymer to create a positively charged hydrogel for valvular engineering. In Chapter 3:
“Acid Scavenger Free Synthesis of Oligo(Poly(Ethylene Glycol) Fumarate) Utilizing Inert
Gas Sparging”, Tissue Engineering: Part C, 2021, 27(5), 296-306, OPF was synthesized in a
one-step process that reduced the number of post-processing steps from tradition synthesis
methods and produced higher molecular weight polymer.2,4 Nitrogen sparged OPF was then
made into hydrogels with poly(ethylene glycol) diacrylate (PEGDA, Mn 575) and shown to
have a modulus within the soft tissue range.
Outlined in Chapter 4: “Charged Oligo(Poly(Ethylene Glycol) Fumarate) Hydrogels
for Encapsulating Valvular Interstitial Cells”, the OPF polymer platform was combined with
a positively charged molecule [2-(methacryloyloxy)ethyl] trimethylammonium chloride
(MAETAC), cell attachment biomolecules, and photoinitiators to make a synthetic hydrogel
for valvular engineering.5–10 To create hydrogels with varying concentrations of positively
charged environments, different concentrations of MAETAC were photocrosslinked into the
polymer network. Crosslinking analysis showed that the charged hydrogels supported
varying concentrations of MAETAC up to 200 mM. Furthermore, a commonly used cell
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attachment peptide (RGD) was tethered to a poly(ethylene glycol) molecule and
photocrosslinked into the polymer network to increase cell attachment and long-term
survival.11–16
A gold standard for photocrosslinking hydrogels is Irgacure 2959 (I2959). Typically,
it took 15-minutes of UV exposer to fully crosslink the charged hydrogels with I2959. To
limit the amount of UV exposure time needed to crosslink the charged hydrogels, the watersoluble photoinitiator lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) was
explored.17 The LAP reduced the UV crosslinking time from 15-minutes to 3-minutes and
was further used as the photoinitiator to make positively charged hydrogels. This work
developed an OPF hydrogel platform with varying concentrations (0-200 mM) of positively
charged monomers that can be UV crosslinked within 3-minutes.
Future iterations of the charged OPF hydrogel platform could incorporate negatively
charged monomers, like sodium methacrylate, to make negatively charged cell environments.
The versatility of the OPF hydrogel could support the addition of another material property
that could play a role in calcific aortic disease progression. Specifically, substrate stiffness
has been shown to cause VICs to differentiate into an osteoblastic phenotype.18 Combining
substate stiffness and environmental charge of the OPF hydrogels could create a 3D calcific
diseases model for further cardiovascular research. Generally, OPF has the potential to be an
ideal candidate for a tissue-specific drug-releasing hydrogel. Through the multiple
unsaturated double-bonds, bioactive molecules can be functionalized into the OPF backbone
and made into a hydrogel. Since the bioactive molecules are covalently bonded to the OPF,
controlled release would depend on the degradation time of the polymer and tissue type.
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Specific Aim 2: Characterize the viability of the walvular interstital cells (VICs) when
exposed to the positively charged OPF hydrogel solution, during UV encapsulation, and in
culture through fluorescent assay analysis.
The positively charged OPF hydrogel was used to encapsulate VICs and test the
cytotoxicity of the materials. Results of cytotoxicity studies are described in Chapter 4:
“Charged Oligo(Poly(Ethylene Glycol) Fumarate) Hydrogels for Encapsulating Valvular
Interstitial Cells”. Initial encapsulation studies showed that VICs did not survive the
encapsulation process, regardless of the presence of the cell attachment biomolecule. The
cytotoxicity of the base OPF hydrogel, without MAETAC, was then investigated. Three
factors were considered as the reason for high cell mortality. The first factor was residual
hydrochloric acid byproduct leftover from synthesizing OPF.2,4 It was found that OPF was
still extremely acidic. Therefore, to neutralize the acidity the OPF hydrogel solution was
reset to a pH of 7.4 with sodium hydroxide. Unfortunately, VICs still did not survive the
encapsulation process so it was hypothesized another factor was also contributing to the
cytotoxicity of the hydrogel.
The second factor investigated was the UV exposure time VICs had to endure during
encapsulation. Originally, the OPF hydrogels were crosslinked with the photoinitiator I2959
which took 15-minutes to completely form the hydrogels. As previously stated, LAP was
investigated as a faster photoinitiator and it reduced the UV exposure time VICs experienced
from 15-minutes to 3-minutes.17 Again, this did not increase cell survival within the OPF
hydrogels.
The final factor that was investigated as a contributor to VICs cytotoxicity was the
polymers that made up the hydrogel solution and scaffolds. Specifically, a conditioned media
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made from leached components of the hydrogel, the hydrogel solution VICs are suspended in
before encapsulation, and the individual polymers (OPF, PEGDA) in a pH 7.4 phosphate
buffer solution were tested for cytotoxicity. The conditioned media showed high cell viability
indicating VICs were dying before encapsulation. The hydrogel solution (pH 7.4) containing
the OPF, PEGDA, and LAP showed moderate cell viability, but extensive cell morphology
changes and VICs were detaching from the plate surface. When the individual OPF
components were tested OPF was found to have high cell viability and VICs remained
attached to the plate surface but VICs exposed to the PEGDA (Mn 575) started to die. Upon
further investigation into PEGDA’s cytotoxicity, it was found that VIC membranes started
forming vesicles and detach from the plate surface. This indicates that PEGDA (Mn 575) was
a major contributor to VIC cell death.19,20
Future work should aim to improve VICs’ survival during encapsulation, specifically,
addressing the OPF acidity and PEGDA crosslinker problems. It is suggested that OPF’s
biocompatibility could be improved through a series of washing steps that would extract
residual hydrochloric acid. Also, using a higher molecular weight PEGDA, around 3400 Da,
has been shown to improve cell viability.19 Once VICs have been shown to survive in OPF
hydrogels further cell studies could aim to test positively and negatively charged
environments on encapsulated VICs to investigate how environmental charged affects VIC
phenotype and if it is a contributing factor to calcific aortic disease progression.

Specific Aim 3: Investigate the chemical and material properties of 1,2-PBF and 1,3-PBF
polymers and crosslinked films.
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The second fumarate-based polymer explored for tissue engineering was PBF.
Poly(butylene fumarate) is a highly viscous hydrophobic polymer that creates stiff plastic
materials that can hydrolytically degrade. In addition, PBF has the ability to be synthesized
with different conformations of butylene which alter the chemical and material properties,
making the polymer ideal for engineering biological interfaces that contain biomechanical
gradients. Using the same acid scavenger free synthesis technique outlined in Chapter 3, PBF
was synthesized with two types of butanediol to investigate the potential of new biomaterials
for engineering the bone-ligament (BL) interface.3,4 The results of synthesizing 1,2-PBF and
1,3-PBF were described in Chapter 5: “Characterization and Development of Poly(1,2Butylene Fumarate) and Poly(1,3-Butylene Fumarate) for Tissue Engineering”. The chemical
and material analysis showed that 1,2-PBF and 1,3-PBF synthesized but did not contain the
same degree of polymerization. The molecular weight of 1,2-PBF was considerably less than
the 1,3-PBF but was found to have a more uniform distribution. It was hypothesized that the
ethyl in the 1,2-butane group causes steric hindrance during polymerization, reducing the
chain length of the polymer.21–23 Differences between the two polymers were also found in
their respective glass transition (Tg) temperatures: 1,3-PBF had a lower Tg than 1,2-PBF. The
difference in Tg can also be attributed to the butylene side groups and how easily the
polymers pack together during phase transitions.
To create stiff crosslinked biomaterials 1,2-PBF and 1,3-PBF were mixed with a
diethyl fumarate crosslinker and the photoinitiator phenylbis(2,4,6-trimethylbenzoyl)
phosphine oxide (BAPO), and cast into films.24,25 The degree of crosslinking of the films was
shown to be high for both PBF polymers. Moreover, 1,2-PBF was found to be more flexible
than the 1,3-PBF films when flexed, indicating the differences, most likely in molecular
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weights, between the 1,2-butylene and 1,3-butylene translate up to crosslinked films. It is
hypothesized that the difference in the flexibility of the films is due to the side group
associated with each PBF polymer and how they affect the crosslinking density of the films.
Future work will need to study the cytotoxicity of 1,2-PBF, in order for the polymers
to be considered biomaterials, and compare biocompatibility to 1,3-PBF and PPF, as a
biomaterial for bone engineering. Specifically, cytotoxicity should focus on relevant cell
types, like osteoblasts or mesenchymal stems cells, to study the biomaterials potential as
bone scaffolds. Also, a systematic comparative analysis between the chemical and material
properties of 1,2-PBF, 1,3-PBF, 1,4-PBF, and PPF would offer insights into their utility in
tissue engineering, creating a catalog of the chemical, materials, and biological properties for
each polymer which could be useful for making scaffolds that mimic the biomechanical and
biochemical gradients found in the bone-ligament interface. Finally, characterizing the
viscosity of the PBF biomaterials is needed to develop them into 3D printable bioinks for
making a bone-ligament construct.
Future Work
Since it was found that VICs did not survive when exposed to the OPF hydrogel
solution due to the OPF acidity and PEGDA (Mn 575) some adaptions to the OPF synthesis
and PEGDA type should be investigated to help improve biocompatibility. To increase the
OPF biocompatibility, post-processing steps should be used to remove residual hydrochloric
acid (HCl) from the OPF polymer. Implementing washing steps using a basic solution will
neutralize the acid but there is a risk of losing OPF in the aqueous phase due to the polymer’s
hydrophilic properties. Alternatively, filtering OPF in dichloromethane through a silica
column could be used to separate the polar hydrochloric acid from the polymer, allowing for
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isolation and collection of the purified OPF. A final precipitation step using ice-cold diethyl
ether and vacuum drying would ensure that any residual organic solvents are completely
removed and the OPF polymer is completely dry. Next, an investigation into the cytotoxicity
of different molecular weights of PEGDA, ranging from 700 – 4,600 g/mole, on VICs should
be run to understand which crosslinker has the highest cell viability. Additionally, an
expanded cytotoxicity study comparing PEGDA molecular weight to the presence of the
acrylate end-groups could delineate which property of PEGDA is causing VIC mortality.
This can be done by exposing VICs to PEGDA or PEG with molecular weights ranging from
575 – 4,600 g/mole and then analyzing cell mortality through a fluorescent live/dead stain.
Furthermore, altering the PEGDA chain length will change the mechanical properties of the
charged OPF hydrogel. It is important that the charged OPF hydrogels have an elastic
modulus within the soft tissue range (10-30 KPa) because VICs respond differently to
substrates with differing mechanical stiffnesses. Therefore, a mechanical properties study
through compression testing would outline the elastic modulus of charged OPF hydrogels
with varying molecular weights of PEGDA. Results would catalog which PEGDA molecular
weights create charged OPF hydrogels within the soft tissue range and are suitable for
culturing VICs in charged OPF hydrogels.
Once the OPF hydrogel system can support VICs for an extended time frame (7days), VICs can be exposed to positively charged environments by incorporation of
MAETAC into the hydrogels, to test if positively charged environments cause an
osteoblastic-like phenotype in VICs. Studies should focus on analyzing key osteoblastic
markers such as calcium deposition from VICs into the extracellular matrix, expression of
intracellular ⍺-smooth muscle actin proteins, and up-regulation of characteristic gene
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markers (⍺-smooth muscle actin, osteocalcin, and transforming growth factor-β1). To
determine calcium deposition a histological analysis using Alizarin Red S staining can be
used and immunohistochemistry can be used to fluorescent stain for ⍺-smooth muscle actin
formation within the cell which would identify cell morphology and ⍺-smooth muscle actin
production. Finally, through DNA isolation and real-time polymerase chain reaction analysis
upregulation of the key osteoblastic gene markers in VICs grown in charged hydrogels can
be used to determine if VICs have become osteoblastic-like. These experiments should
increase the understanding of how charged biomaterials can affect the phenotype of VICs.
The next steps to develop 1,2-PBF and 1,3-PBF into a biomaterial for tissue
engineering applications and bioprinting bone scaffolds includes determining the material’s
capacity to culture cells on, followed by materials studies that optimize the printing
parameters of PBFs’ bioinks. If both PBF bioinks are to be considered biomaterials they must
be able to support cell growth. To confirm biocompatibility cell attachment and viability
studies will need to be run. Additionally, since PBFs are being developed for bioprinting
bone scaffolds, osteoblasts should be used to determine cell attachment and growth on the
materials. To study the biocompatibility of the materials a fluorescent live/dead and
metabolic assay can be used, followed by actin and myosin immunohistochemical staining
and cell attachment assays to determine osteoblast’s ability to attach and spread on the PBF
materials. Once osteoblasts have been shown to survive on the materials, then an
investigation into phenotypic expression of cultured osteoblasts can be run. Specific cell
expressions that should be studied for osteoblasts are the production of extracellular
products, like calcium deposition, through an Alizarin Red S stain to understand if 1,2-PBF
and 1,3-PBF stimulate bone formation. Furthermore, genetic studies using real-time
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polymerase chain reaction can be run to determine the up-regulation of osteoblastic genes
used in bone remodeling, like alkaline phosphatase, type I collagen, osteopontin, and
osteocalcin.
Upon determining that 1,2-PBF and 1,3-PBF can support osteoblast growth and
proper phenotypic expression, 3D bioprinting studies should be run to outline parameters
needed to print 1,2-PBF and 1,3-PBF bioinks into 3D porous scaffolds. Initially, a study of
the viscosity of each bioink using rheometry will have to be run to help determine fluid flow
properties during printing parameter optimization. Printing parameters such as the size and
shape of the printing nozzle, extrusion pressure, printing speed and height, and UV curing
time will need to be outlined in order to print high-resolution 3D scaffolds. To determine the
size and shape of the printing nozzle and extrusion pressure a factorial design can be set up to
systematically test the bioinks’ ability to flow through each nozzle type with increasing
amounts of extrusion pressures. Successful nozzles and extrusion pressures will allow a
constant stream of bioink flows. Next, printing speed, height, and UV curing time can be
tested by printing lines of bioinks at varying print speeds, heights, and UV curing times. The
printed lines then can be analyzed through microscopic imaging and software analysis of the
line’s geometry. Successful printing speeds, heights, and UV curing times will result in an
intact line with a tubular geometry, while a line that missing sections and has a flattened
geometry will indicate a fast-printing speed, low printing height, or inadequate UV curing.
Finally, after printing parameters have been optimized 3D porous scaffolds can be printed
with 1,2-PBF and 1,3-PBF and the architecture of the scaffolds can be analyzed. Specifically,
the scaffolds’ strut shape, spacing, and pore dimensions can be measured through
microscopic imaging and software analysis. The strut shape, distance, and pore circularity
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will help determine the print resolution of the PBF scaffolds. By characterizing the PBFs’
ability to grow osteoblasts and outlining printing parameters, 1,2-PBF and 1,3-PBF bioinks
can be printed into 3D porous bone scaffolds for future bone tissue engineering applications.
Broader Impact
Overall, this work highlights two uses of fumarate-based polymers for tissue
engineering applications. First, using OPF it was shown that a positively charged hydrogel
system has the potential for valvular engineering. Further development of the charged OPF
hydrogel system will aid in studying cell-material interactions of environment charge on VIC
phenotype. This will further increase the current understanding of how the extracellular
environments affect the progression of calcific valvular disease and aid in treatment
development.
This work also reflects the investigation of chemically engineered PBF as a
biomaterial for replicating the bone-ligament interface. New biomaterials are needed to help
replicate complex systems found in the body such as the bone-ligament enthesis. As such,
1,2-PBF has never been investigated as a biomaterial for tissue engineering applications and
has the potential of being a biomaterial for bone and osteochondral tissue. Moreover, PBF
has the potential to be a bioprintable material for printing composite scaffolds that replicate
the bone-ligament interface. Variations of PBF are a newer class of fumarate-based polymer
and possibly can be used in 3D cell modeling and fabrication of a complex bone-ligamentbone medical device.
Finally, this work outlines the uses of fumarate-based polymers as tissue-engineered
scaffolds for valvular research and bone tissue. Further research into current fumarate-based
polymers offers an ability to make both soft and hard tissues that have tunable biomechanical

160

and biochemical gradients, ideal for replicating complex tissue interfaces. These polymers
also have applications in additive manufacturing which extends past traditional scaffold
processing techniques, like casting, into detailed scaffold platforms that mimic the tissue
architecture. Further research and application of fumarate-based polymers show their utility
not only in the tissue engineering and regenerative medicine field but also as biomaterials for
other additive manufacturing applications, cell and organ modeling, and medical device
development.
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